NEW APPROACHES TO MENTAL ILLNESS
IN THE
ERA OF THE NATIONAL BRAIN INITIATIVE
ASCP ANNUAL MEETING
June 16 - 19, 2014
HOLLYWOOD, FL
www.ASCPMeeting.org
Dear Colleagues:
On behalf of the American Society of Clinical Psychopharmacology
(ASCP), we are very pleased to welcome you to this year’s “ASCP Annual
Meeting.” In 2010, several decisions were made that allowed ASCP to
reinvent NCDEU as “the New NCDEU.” Over the last three years “the
New NCDEU” has been quite successful. Moving forward in 2014, the
ASCP Board and the ASCP/NCDEU Steering Committee have decided to
rename the meeting the “ASCP Annual Meeting.”
The ASCP is proud to sponsor the meeting, now in its 54th year.
Psychopharmacology is an exciting field undergoing dramatic changes,
with the identification of new molecular targets and the development
of novel compounds. Our Society keeps its members abreast of
such innovations. Our annual meeting serves as the vehicle for the
dissemination of cutting edge psychopharmacology research. We will
continue to develop ways for members to feel more connected with our
Society and to include more clinically focused symposia.
Another major goal for ASCP is to increase its visibility to those
interested in the practice of psychopharmacology, thereby helping our
membership grow. With over 1,000 annual attendees, the meeting has
also become a key opportunity for networking, planning and to develop
the next generation of clinical researchers.
A very special thank you to the members of the ASCP/NCDEU Steering
and ASCP Program Committees for their critical role in the success of the
meeting. We are all looking forward to an exciting and highly informative
ASCP Annual Meeting.
Maurizio Fava, M.D.
President
American Society of Clinical Psychopharmacology
Welcome to the ASCP Annual Meeting
On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to
the ASCP Annual Meeting. Though the name of the meeting has changed, the ASCP is committed to continue
to build on the past success of NCDEU with program innovation while preserving the rich history of this meeting.
Below are some of the highlights of the 2014 meeting.
The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators,
National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.
• 2014 Program Highlights
oMonday, June 16
§Conference Opening
§Pharma Pipeline: 10 presentations of Phase 1 and Phase 2 developments.
oTuesday, June 17
§15th Annual Fun Run/Walk
§Regulatory Plenary: FDA Science Initiatives: A Brief Update
§ASCP Lifetime Awardee Talk
§Poster Session I
§ASCP Reception
oWednesday, June 18
§Keynote Plenary Session: New Approaches to Mental Illness in the Era of the National Brain
Initiative
§NIH Institute Directors Plenary
§Poster Session II
§Updates Session – The Latest on Treatment of Mood, OCD-spectrum, and Binge Eating
Disorders
§Workshops
oThursday, June 19
§Regulatory Wrap-Up Plenary with the FDA
oThroughout the meeting
§NIMH, NIDA, NCCAM, and NIAAA panels
oThe New Investigator Program
§A closed workshop for 20 New Investigators and informal breakfast sessions
oWorkshops: 2 hour intensive interactive sessions focused on problems and solutions
§Tuesday and Wednesday Afternoons
o*Clinical Track* – sessions focused on topics of immediate clinical relevance
• Organization
oThe meeting is sponsored by the American Society for Clinical Psychopharmacology (ASCP).
§The Steering Committee organizes the meeting.
§The Program Committee evaluates submitted proposals and develops program innovations.
oNIH collaborations:
§NIMH - National Institute of Mental Health
§NIDA - National Institute of Drug Abuse
§NIAAA National Institute on Alcohol Abuse and Alcoholism
§NCCAM - National Center for Complementary and Alternative Medicine
§CSR – Center for Scientific Review
§NCATS - National Center for Advancing Translational Sciences
oRegulatory agency collaborations:
§Food and Drug Administration (FDA)
oParthenon Management Group organizes the ASCP Annual Meeting.
• And remember
oThe Opening Reception is Tuesday, June 17th from 7:00 pm – 8:00 pm.
oThe Fun Run/Walk is Tuesday, June 17th at 6:45 am.
The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to
make the event even better. Seek us out during the meeting or provide your views by completing the evaluation
form.
Best Regards,
Husseini Manji, M.D., FRCPC
Steering Committee Co-Chair
Michael E. Thase, M.D.
Steering Committee Co-Chair
Carlos Zarate, M.D.
Program Committee Co-Chair
Holly A. Swartz, M.D.
Program Committee Co-Chair
Hotel Maps
2nd Floor Convention Center
GRAND
BALLROOM
WEST
ATLANTIC
BALLROOM
3
SERVICE CORRIDOR
GRAND
BALLROOM
EAST
REGENCY
BALLROOM
3
ATLANTIC
BALLROOM
2
REGENCY
BALLROOM
2
ATLANTIC
BALLROOM
1
M
REGISTRATION
CONVENTION
CENTER
THE WESTIN
DIPLOMAT
FREIGHT
ELEVATOR
REGENCY
BALLROOM
1
W
5
SERVICE CORRIDOR
SERVICE
ELEVATORS
4
DIPLOMAT
BALLROOM
3
1
2
S
ESCALATOR
ELEVATORS
W
E
TERRACE
N
WALKWAY
TO RESORT
Resort, Second Floor
NORTH
TOWER
TER
ACE
203
202
204
SOUTH
TOWER
RAC
TERR
220
201
E
CONVENTION
CENTER
THE WESTIN
DIPLOMAT
218
219
217
ESCALATORS
216
205
SERVICE
ELEVATORS
SERVICE
ELEVATORS
ELEVATORS
M
W
206
SKYWALK
WALKWAY TO
CONVENTION
CENTER
ELEVATORS
W
209
M
215
208
E
207
EXECUTIVE
OFFICES
212
BUSINESS
CENTER
TERRACE
213
214
S
N
W
2
Hotel Maps
Resort, Third Floor
NORTH
TOWER
302
303
RAC
E
320
301
322
305
SOUTH
TOWER
TER
CE
A
TERR
THE WESTIN
DIPLOMAT
CONVENTION
CENTER
318
319
317
321
ESCALATOR
316
ESCALATOR
SERVICE
ELEVATORS
SERVICE
ELEVATORS
ELEVATORS
M
W
306
SKYWALK
ELEVATORS
309
310
308
311
W
M
315
E
312
307
313
314
S
N
EXECUTIVE
OFFICES
TERRACE
W
Future ASCP Meetings
• State of the Art – Fall Psychopharmacology Update Meeting
October 11-12, 2014
New York, New York
• 2015 ASCP Annual Meeting
June 22-25, 2015
Miami Beach, Florida
3
Table of Contents
Award Winners and Featured Speakers............................................5
Acknowledgements.......................................................................15
Meeting Announcements...............................................................21
Sunday, June 15, 2014...................................................................25
Monday, June 16, 2014.................................................................27
Tuesday, June 17, 2014..................................................................41
Wednesday, June 18, 2014............................................................53
Thursday, June 19, 2014................................................................63
Poster Session 1.............................................................................69
Poster Session 2.............................................................................81
Author Index.................................................................................93
DISCLOSURES FOR ALL ASCP PRESENTERS
CAN BE VIEWED AT WWW.ASCPMEETING.ORG
4
Recipient of the Donald Klein Lifetime Achievement Award
A. John Rush, M.D.
Duke-National University of Singapore
Dr. Rush majored in Biochemistry at Princeton and completed
his M.D. at Columbia College of Physicians and Surgeons.
Following his internship in general medicine (Passavant Hospital,
Northwestern University), he served in the U.S. Army before
joining the Special Action Office for Drug Abuse Prevention in
Washington D.C. After his psychiatric residency at the University of
Pennsylvania, he became Assistant Professor at the University of
Oklahoma and subsequently joined the Departments of Psychiatry
and later the Department of Clinical Sciences at the University of Texas Southwestern
Medical Center at Dallas. In 2008, he became Vice Dean of Clinical Sciences and
Professor at Duke-NUS (Singapore).
At Duke-NUS he founded and developed several programs designed to advance
patient oriented research careers of medical, surgical and mental health, nursing
and allied health practitioners including the Academic Medicine Research Institute,
the Center for Quantitative Medicine, and the Medical Student III program in clinical
research.
His research has focused on the development and testing of innovative treatments for
mood disorders including medications, medication combinations, somatic treatments,
psychotherapy, and disease management protocols (treatment algorithms). He
has authored more than 600 papers and chapters and 10 books. He was Principal
Investigator on the NIMH sponsored STAR*D (Sequenced Treatment Alternatives to
Relieve Depression) trial and directed the NIMH Depression Trials Network (DTN).
Past awards include the Mood Disorders Research Award (American College of
Psychiatrists), the Paul Hoch Award (American Psychopathological Association), the
Edward J. Sachar Award (Columbia College of P & S), the Nola Maddox Falcone Prize
(NARSAD), the American Psychiatric Association Award for Research in Psychiatry, and
the Gold Medal Award (Society of Biological Psychiatry). He has served as President
of the Society of Biological Psychiatry and Society for Psychotherapy Research.
He presently provides consultation to academic centers, government and industrial
organizations and entities.
5
Awards Winners &
Featured Speakers
Award Winners
Award Winners
Recipient of the Paul Wender Best Paper
in the Journal of Clinical Psychiatry Award
Sophie Grigoriadias, M.D.
Sunnybrook Health Sciences Centre
Nominated for: Antidepressant Exposure During Pregnancy
and Congenital Malformations: Is There an Association? A
Systematic Review and Meta-Analysis of the Best Evidence
Sophie Grigoriadis, M.D., Ph.D., FRCPC; Emily H. VonderPorten,
MPH; Lana Mamisashvili, MSW; Michael Roerecke, Ph.D.; Jürgen
Rehm, Ph.D.; Cindy-Lee Dennis, Ph.D.; Gideon Koren, M.D.,
FRCPC, FACMT; Meir Steiner, M.D., Ph.D., FRCPC; Patricia Mousmanis, M.D., CCFP,
FCFP; Amy Cheung, M.D., MSc, FRCPC; and Lori E. Ross, Ph.D.
Dr. Grigoriadis is the Head of the Women’s Mood and Anxiety Clinic: Reproductive
Transitions at Sunnybrook health Sciences Centre and scientist at the Sunnybrook
Research Institute. She was the Academic Leader of the Reproductive Life Stages
Program at Women’s College Hospital, Fellowship Director in the department of
psychiatry at the University Health Network (UHN) and a Staff Psychiatrist at both sites
including the Mood Disorders Psychopharmacology Unit at UHN until September 2011.
She is an Associate Professor in the Mood and Anxiety Disorders and Women’s Mental
Health Programs, Department of Psychiatry, Faculty of Medicine, at the University of
Toronto.
Dr. Grigoriadis completed her medical degree at McMaster University and her
psychiatry residency at the University of Toronto. Prior to Medical school, she
completed a MA and Ph.D. in Clinical Psychology at Queen’s University, and internship
in Clinical Psychology at the Toronto Hospital. Dr. Grigoriadis’ clinical interests include
women with depression especially during pregnancy, the postpartum period and during
perimenopause. Her treatment strategies include both the use of pharmacotherapy
as well as short-term psychotherapies. Current research focuses on the presentation
of mood disorders in women across the lifespan, hormonal influences in the
presentation and treatment of depression during the postpartum and perimenopause,
and differences in the presentation and response to antidepressant medications
among women of various ages. Dr. Grigoriadis is also actively involved in developing
novel treatment strategies for depression. She is currently leading several studies
including developing a tool to assist clinicians in making treatment decisions with their
depressed perinatal patients and is developing treatment guidelines for the treatment
of depression during the perimenopause. She is an author in the Canadian Guidelines
for the Treatment of Depression. Her educational activities include teaching psychiatry
residents, training family practice as well as psychiatry residents in Interpersonal
Psychotherapy and teaching in continuing medical education programs.
6
Featured Speakers
Regulatory Plenary - FDA Science Initiatives: A Brief Update
Tuesday, June 17, 2014 from 8:30 am – 10:00 am
Ni Khin, M.D.
Food and Drug Administration
Dr. Ni Khin is Acting Division Director in Division of Good Clinical
Practice Compliance, Office of Scientific Investigations, Center for
Drug Evaluation and Research, FDA. She has served as Medical
Team Leader in the Division of Psychiatry Products, Office of New
Drugs for past 8 years. In this position, she oversaw the review
of clinical protocols submitted under investigational new drug
applications (INDs) for all phases of drug development. She also
managed, as cross-disciplinary team leader, regulatory and clinical reviews of New
Drug Applications (NDAs) for all psychiatric indications. She joined the Agency in 2001
as a Clinical Reviewer in the Division of Neuropharmacologic Drug Products. She
also worked as Medical Officer and Branch Chief of Good Clinical Practice Branch 1,
Division of Scientific Investigations, where she provided scientific oversight for CDERassigned bioresearch monitoring (BIMO) activities. She conducted on-site data-audit
inspections of clinical trial sites both in the US and abroad. Prior to coming to FDA,
Dr. Khin was a Senior Staff Fellow in the Geriatric Psychiatry Branch at the National
Institute of Mental Health.
Dr. Khin received her medical degree from the Institute of Medicine I, Rangoon, Burma
(Myanmar). She completed residency training in Psychiatry at the State University
of New York, Buffalo. She is board-certified in Psychiatry by the American Board of
Psychiatry and Neurology. She also received a Master of Science Degree from Arizona
State University. Her regulatory research interest includes trial design and methodology
to improve detection of efficacy signals as well as regulatory and scientific issues
regarding use of foreign data from global trials in support of NDA’s.
Celia Winchell, M.D.
Food and Drug Administration
Celia Winchell is the Medical Team Leader for Addiction Products in the FDA’s Division
of Anesthesia, Analgesia, and Addiction Products in the Center for Drug Evaluation and
Research. Since 1995, Dr. Winchell has been providing regulatory oversight for drug
development in all aspects of addiction treatment, and for academic research involving
drugs of abuse. Dr. Winchell holds a bachelor’s degree in psychology from Harvard
University, and a medical degree from the University of Virginia. She completed
residency training in psychiatry at Johns Hopkins Hospital.
7
Featured Speakers
Silvana Borges, M.D.
Food and Drug Administration
Dr. Borges received her medical degree from the State University
School of Medicine in Uruguay. She completed her medical residency
and is board certified in Child & Adolescent Psychiatry. She joined the
Department of Pharmacology and Therapeutics in the State University
School of Medicine as an Assistant Professor and then became an Assistant Professor and
Founding Member of the “National Center for Drug Safety” in Uruguay. She was a Scholar at
the Catalan Institute of Pharmacology (Barcelona, Spain) focusing her training in drug safety
and pharmacoepidemiology. She received the Merck Foundation International Fellowship
in Clinical Pharmacology Award and completed a fellowship in clinical pharmacology
and pharmacogenetics at Indiana University, being mentored by Dr. David Flockhart. She
was the recipient of the American Society for Clinical Pharmacology and Therapeutics
Presidential Trainee Award for her work on the role of CYP2D6 genetic polymorphism on
tamoxifen metabolism and its interaction with antidepressants. She joined the FDA in 2007
and is currently an Acting Clinical Team Leader with the Division of Psychiatry Products,
Office of New Drugs, Center for Drug Evaluation and Research.
Plenary: New Approaches to Mental Illness in the Era of the
National Brain Initiative
Wednesday, June 18, 2014 from 8:15 am - 9:45 am
Husseini Manji, M.D., FRCPC
Johnson & Johnson Pharmaceutical Research &
Development
Husseini K. Manji, M.D., FRCPC, is Global Therapeutic Head for
Neuroscience at Janssen Research & Development, LLC, a division of
Johnson & Johnson. Previously, he was Chief, Laboratory of Molecular
Pathophysiology & Experimental Therapeutics, NIH, and Director of the NIH Mood and
Anxiety Disorders Program. Dr. Manji received his B.S. and M.D. from the University of
British Columbia. He completed fellowship training at the NIMH and completed additional
training in cellular and molecular biology. His research has focused on investigation of
disease-and treatment-induced changes in gene and protein networks that regulate
synaptic and neural plasticity. His work has led to investigation of novel therapeutics for
patients with refractory neuropsychiatric illnesses. Dr. Manji has also been involved in
medical and postgraduate neuroscience education and has published extensively on the
molecular and cellular neurobiology of neuropsychiatric disorders and the development of
novel therapeutics. Dr. Manji has received numerous distinguished scientific and academic
awards, including the NIMH Director’s Career Award for Significant Scientific Achievement,
and was inducted in to the U.S. Institute of Medicine of the National Academies in 2008. He
has served as Chair of the American College of Neuropsychopharmacology, is a Counselor
to the Society of Biological Psychiatry and serves on a variety of editorial boards of
scholarly journals. He holds voluntary leadership positions in many organizations devoted
to advancement of neuroscience and advocacy for people with neuropsychiatric illnesses.
He has been a member of the Howard Hughes Medical Institute and NIH Research Scholars
Program Advisory Committee.
8
Featured Speakers
Thomas Insel, M.D.
National Institute of Mental Health
Thomas R. Insel, M.D., is Director of the National Institute of
Mental Health (NIMH), the component of the National Institutes
of Health charged with generating knowledge to understand,
treat and prevent mental disorders. His tenure at NIMH has been
distinguished by groundbreaking findings on the genetics and
neurobiology of mental disorders ads well as efforts to transform
the diagnosis and treatment of serious mental illnesses. In addition
to his leadership of the NIMH, Dr. Insel has served as Chair of the Interagency Autism
Coordinating Committee (Since 2002), co-chair of the NIH Blueprint for Neuroscience
Research (since 2004), and Acting Director of the National Center for Advancing
Translational Science (2011-2012). Currently, Dr. Insel is on the leaders for the NIH
Brain Research through Advancing Innovative Neurotechnologies (BRAIN) effort, a
Presidential initiative focused on developing new tools for understanding the brain.
Prior to his appointment as NIHM Director in the Fall 2002, Dr. Insel was Professor
of Psychiatry at Emory University. There, he was founding director of the Center for
Behavioral Neuroscience and director of an NIH-funded Center for Autism Research.
From 1994 to 1999, he was Director of the Yerkes Regional Primate Research Center
in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at
NIMH, studying the neurobiology of complex social behaviors. He has published over
280 scientific articles and four books, including the Neurobiology of Parental Care (with
Michael Numan) in 2003.
Dr. Insel is a member of the Institute of Medicine, a fellow of the American College
of Neuropsychopharmacology, and is a recipient of several awards, including the
Outstanding Service Award from the U.S. Public Health Service and the 2010 La
Foundation IPSEN Neuronal Plasticity Prize. Dr. Insel graduated from the combined
B.A.-M.D. program at Boston University in 1974. He did his internship at Berkshire
Medical Center, Pittsfield, Massachusetts, and his residency at the Langley Porter
Neuropsychiatric Institute at the University of California, San Francisco.
9
Featured Speakers
Patrick Kennedy
Former US Representative and Mental Health
Activist
Patrick J. Kennedy became the youngest member of the Kennedy
family to hold elected office when, in 1988, he won election to the
Rhode Island House of Representatives at age 21. Since then,
Kennedy went on to serve 16 years in the United States House of
Representatives, representing Rhode Island’s first congressional
district from 1994 to 2011. While in office, he distinguished himself
as a leader on issues of healthcare, sciences, veterans, technology, civil rights, and
mental health.
As a founding member of the 21st Century Healthcare Caucus; the Addiction,
Treatment and Recovery Caucus; and the Down Syndrome Caucus, Kennedy has been
a tireless advocate for access to health and advancements in medical research.
Throughout his career, Kennedy has been a vocal advocate for healthcare reform.
He was the author and chief House sponsor of the Wellstone-Domenici Mental
Health Parity and Addiction Equity Act of 2008, an act that expanded access to
mental health services to over 100 million Americans. He has also authored and cosponsored dozens of bills to increase the understanding and treatment of neurological
and psychiatric disorders, including the National Neurotechnology Initiative Act, the
Genomics and Personalized Medicine Act, the Combat PTSD Act, and the Alzheimer’s
Treatment and Caregiver Support Act.
Since leaving office in 2011, Patrick J. Kennedy has been devoting his efforts to
promoting research in neuroscience. He co-founded One Mind for Research, a
nonprofit organization, the mission of which is to be the leader in brain research
in order to eliminate stigma, transform policy, and allocate resources that will help
both our understanding and treatment of brain diseases. In addition to One Mind
for Research, Kennedy is also an active board member of Best Buddies, Research
America, and the Edward M. Kennedy Institute for the United States Senate.
The champion of mental health in Congress who believes that “the brain is the last
medical frontier.” Patrick J. Kennedy is a sought-after speaker on mental health,
healthcare, and many other related issues. He was invited by House Minority Leader
Nancy Pelosi to address the Democratic Caucus on mental health and will launch
the Kennedy Forum on Community Mental Health. In 2013, he spoke at the National
Institute of Mental Health Alliance for Research Progress, the US/Canada Forum on
Mental Health and Productivity, and the Mental Health America Conference.
10
Featured Speakers
Institute Directors Plenary
Wednesday, June 18, 2014 from 10:00 am – 12:00 pm
Thomas Insel, M.D.
National Institute of Mental Health
See previous bio
Phillip Skolnick, Ph.D., D.Sc. (hon.)
National Institute on Drug Abuse
Phil Skolnick is the Director, Division of Pharmacotherapies and
Medical Consequences of Drug Abuse at the National Institute on
Drug Abuse, NIH. Dr. Skolnick served as Chief Scientific Officer
(2001-2009) and President (2007-2009) of DOV Pharmaceutical,
Inc. He was also Research Professor of Psychiatry (2001-2009)
and a member of the Center of Excellence on Drug Addiction at
New York University-Langone Medical Center. Dr. Skolnick was a
Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000). Prior
to this, he was a Senior Investigator and Chief, Laboratory of Neuroscience, at the NIH
intramural research program (1986-1997). Dr. Skolnick has also served as a Research
Professor of Psychiatry at the Uniformed Services University of the Health Sciences,
Adjunct Professor of Anesthesiology at Johns Hopkins University, and Adjunct
Professor of Pharmacology and Toxicology at Indiana University School of Medicine.
He received a Ph.D. from the Department of Pharmacology, George Washington
University School of Medicine (1972), and served as a Staff Fellow and Senior Staff
Fellow at the NIH under Dr. John W. Daly (1972-1977).
His awards and honors include the Experimental Therapeutics Prize from the American
Society for Pharmacology and Experimental Therapeutics, an Anna Monika Prize,
and the A.E. Bennett Award in Biological Psychiatry. He has twice been awarded the
Doctor of Science, honoris causa. Dr. Skolnick has co-authored more than 500 articles
and currently serves on the editorial advisory board of seven journals. He is currently
an editor of Current Protocols in Neuroscience, and has also edited six books. The
Institute of Scientific Information (ISI) has acknowledged his contributions by naming
him to the elite group of “Highly Cited” authors.
11
Featured Speakers
Kenneth Warren, Ph.D., D.Sc.
National Institute on Alcohol Abuse and Alcoholism
Kenneth R. Warren, Ph.D., a nationally-recognized expert on alcohol
and pregnancy, and a long-time senior administrator at the National
Institute on Alcohol Abuse and Alcoholism (NIAAA) became Acting
Director of NIAAA on November 1, 2008, following the retirement of
Ting-Kai Li, M.D. on October 31, 2008. Dr. Li had served as NIAAA
Director from September 2002 through October 2008. Dr. Warren
was named as the NIAAA Deputy Director in February 2008. He
held numerous positions in NIAAA since joining the Institute in 1976.
A graduate of the City College of New York, Dr. Warren earned his doctorate degree
in Biochemistry from Michigan State University in 1970. He subsequently undertook
postdoctoral positions at the University of California, Los Angeles and at University of
Michigan Mental Health Research Institute before joining the Federal government in a
research position at the Walter Reed Army Institute of Research in 1974.
Dr. Warren has maintained an active interest in all areas of alcohol and health and in
past years often served as the editor of the triennial Reports to Congress on Alcohol and
Health. He has been particularly active in research on the effects of alcohol use during
pregnancy, including fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorders
(FASD). Dr. Warren initiated NIAAA’s research program on FAS over 30 years ago. He
currently chairs the government-wide Interagency Coordinating Committee on FAS.
Dr. Warren has received numerous honors, including a superior service award from the
Public Health Service in 1982 for his work in development of the first Surgeon General’s
Advisory on FAS. In 2007, the National Organization on Fetal Alcohol Syndrome (NOFAS)
honored Dr. Warren by placing his name into their Tom and Linda Daschle FASD Hall of
Fame, followed by the receipt of the NOFAS Excellence Award in 2008.
Christopher P. Austin, M.D.
National Center for Advancing Transitional
Sciences
In September 2012, NIH Director Francis S. Collins announced
the appointment of Christopher P. Austin, M.D., as director of the
National Center for Advancing Translational Sciences (NCATS). Austin
succeeded former acting director of NCATS and current director of
the National Institute of Mental Health Thomas R. Insel, M.D.
Austin, who served as director of the NCATS Division of Pre-clinical Innovation since the
creation of the Center in December 2011, is leading NCATS in its mission to catalyze the
generation of innovative methods and technologies that will enhance the development,
testing and implementation of diagnostics and therapeutics across a wide range of human
diseases and conditions. Currently, many costly, time-consuming bottlenecks exist in
the translational pipeline. Austin is applying his experiences in nearly every stage of the
research pipeline to build on the Center’s momentum in finding innovative ways to reduce,
remove or bypass these bottlenecks and speed the delivery of new drugs, diagnostics
and medical devices to patients.
12
Featured Speakers
After working at Merck on genome-based discovery of novel targets and drugs, Austin
began his NIH career in 2002 as the Senior Advisor to the Director for translational
research at the National Human Genome Research Institute, where he initiated the
Knockout Mouse Project and the Molecular Libraries Roadmap Initiative. Other NIH roles
have included serving as Director of the Therapeutics for Rare and Neglected Diseases
program as well as the NIH Chemical Genomics Center and as Scientific Director of the
NIH Center for Translational Therapeutics.
Austin earned a medical degree from Harvard Medical School and an undergraduate
degree in biology from Princeton University. He completed clinical training in internal
medicine and neurology at Massachusetts General Hospital as well as a fellowship in
genetics at Harvard.
Richard Nakaruma, M.D.
Center for Scientific Review
Dr. Richard K. Nakamura is the Director of the Center for Scientific
Review. In that capacity, he leads the review of grant applications
of the National Institutes of Health. Dr. Nakamura received his
Bachelor of Arts in Psychology from Earlham College and his Ph.D. in
Psychology from State University of New York (Stony Brook, NY). He
was with the National Institute of Mental Health from 1976 to 2011.
In 2001, he received the NIH-Asian/Pacific American Organization
(APAO) Outstanding Achievement Award for Administrative Work.
In 2002, Dr. Nakamura was elected by the American Association for the Advancement of
Science (AAAS) to the status of AAAS Fellow. Also in 2002, Dr. Nakamura was awarded
the Presidential Rank Award for outstanding leadership. In 2004 and 2005, respectively, he
received leadership awards from the Federation of Behavioral Psychological and Cognitive
Sciences, and from the International Society for Behavioral Neuroscience. In 2009, he
was awarded the NIH Director’s Award for Outstanding Administration.
Josephine Briggs, M.D.
National Center for Complementary and Alternative
Medicine
An accomplished researcher and physician, Dr. Briggs received her
A.B. in biology from Harvard-Radcliffe College and her M.D. from
Harvard Medical School. Previous to her appointment at NCCAM,
she was director of the Division of Kidney, Urologic, and Hematologic
Diseases at the NIH National Institute of Diabetes and Digestive and
Kidney Diseases. In 2006, Dr. Briggs became Senior Scientific Officer
at the Howard Hughes Medical Institute. In January 2008, she returned to NIH as the
NCCAM Director.
13
Featured Speakers
Regulatory Wrap-Up
Thursday, June 19, 2014 from 10:15 am – 11:45 am
Ni Khin, M.D.
Food and Drug Administration
See previous bio
Celia Winchell, M.D.
Food and Drug Administration
See previous bio
Silvana Borges, M.D.
Food and Drug Administration
See previous bio
Phillip Kronstein, M.D.
Food and Drug Administration, CDER
Phillip Kronstein, M.D., is a Senior Medical Officer in the
Division of Psychiatry Products (DPP) at the U.S. Food and
Drug Administration’s Center for Drug Evaluation and Research
(CDER). In this position, Dr. Kronstein manages clinical reviews
of Investigational New Drugs (INDs) and New Drug Applications
(NDAs). Prior to joining the FDA in January 2008, he was a
Clinical Research Fellow in the Experimental Therapeutics and
Pathophysiology Branch at the National Institute of Mental Health, where he conducted
trials in treatment-resistant depression and bipolar disorder. He received a Bachelor’s
of Science in Chemistry from the University of Chicago in 1995 and a Doctor of
Medicine from Tufts University School of Medicine in 2001. He completed his residency
training in Psychiatry at the Johns Hopkins Hospital in June 2005. In addition to
his review responsibilities at the FDA, Dr. Kronstein has been involved in regulatory
research, looking at sexual dysfunction with antidepressants. He is also the Division
Data Standards Lead for DPP as CDER, as part of a larger FDA initiative, continues
to develop and implement standards to represent study data submitted in support of
regulatory applications.
14
Acknowledgements
Steering Committee Chairs
Husseini Manji, M.D., FRCPC
Michael E. Thase, M.D.
Program Chairs
Carlos Zarate, M.D.
Holly A. Swartz, M.D.
New Investigator Award Program Chairs
Lauren D. Hill, Ph.D.
Mark H. Rapaport, M.D.
15
Acknowledgements
Acknowledgements
Steering Committee Members
Karl Broich, M.D.
Federal Institute of Drugs and Medical Devices
«Lori Davis, M.D.
Tuscaloosa VA Medical Center
Maurizio Fava, M.D.
The Massachusetts General Hospital (ASCP Board Member)
Marlene Freeman, M.D.
Harvard Medical School (ASCP Board Member)
Bruce Kinon, M.D.
Eli Lilly & Company
James H. Kocsis, M.D.
Weill-Cornell Medical College
David J. Kupfer, M.D.
University of Pittsburgh School of Medicine
Thomas P. Laughren, M.D.
Food and Drug Administration
Raye Litten, Ph.D.
National Institute of Alcohol Abuse and Alcoholism
«Anil K. Malhotra, M.D.
Hofstra NS-LIJ School of Medicine
The Zucker Hillside Hospital
Husseini K. Manji, M.D., FRCPC
Johnson & Johnson Pharmaceutical Research & Development
Steve Marder, M.D.
University of California Los Angeles
David Michelson, M.D.
Merck & Company, Inc.
Andrew A. Nierenberg, M.D.
Massachusetts General Hospital
William Z. Potter, M.D., Ph.D.
Foundation for the National Institute of Health
Stephanie O’Malley, Ph.D.
Yale University School of Medicine
«New Investigator Alumni
s Representing
16
ASCP CME Committee
Acknowledgements
Steering Committee Members (continued)
s
Mark H. Rapaport, M.D.
Emory University School of Medicine (ASCP Board Member)
Bob A. Rappaport, M.D.
Center for Drug Evaluation and Research, FDA
Steve Romano, M.D.
Pfizer, Inc.
Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center
Philip Skolnick, Ph.D., D.Sc.
National Institute on Drug Abuse
Michael Thase, M.D.
University of Pennsylvania School of Medicine (ASCP Board Member)
Ben Vitiello, M.D.
National Institute of Mental Health
«Carlos A. Zarate, M.D.
National Institute of Mental Health
Program Committee
Leslie Citrome, M.D., M.P.H.
New York Medical College (ASCP Board Member)
«Christoph U. Correll, M.D.
The Zucker Hillside Hospital (ASCP Board Member)
Thilo Deckersbach, Ph.D.
Massachusetts General Hospital
Bryan L. Dirks, M.D.
Shire Pharmaceuticals
Eden Evins, M.D.
Harvard Medical School
«Tiffany R. Farchione, M.D.
Food and Drug Administration
Maurizio Fava, M.D.
Massachusetts General Hospital (ASCP Board Member)
Bradley Gaynes, M.D.
University of North Carolina
«New Investigator Alumni
s Representing
17
ASCP CME Committee
Acknowledgements
Program Committee (continued)
John Greist, M.D.
Healthcare Technology Systems, Inc.
Richard Keefe, Ph.D.
Duke University Medical Center
Terence Ketter, M.D.
Stanford University School of Medicine
Helena Kraemer, Ph.D.
Stanford University
Charlotte Kremer, M.D.
Astellas Pharmaceuticals
David J. Kupfer, M.D.
University of Pittsburgh School of Medicine
Thomas P. Laughren, M.D.
Food and Drug Administration
«Anil Malhotra, M.D.
Hofstra NS-LIJ School of Medicine, The Zucker Hillside Hospital
Stephen Marder, M.D.
Semel Institute, UCLA
s
Craig Nelson, M.D.
University of California San Francisco
«Katharine Phillips, M.D.
Rhode Island Hospital/Brown University
Steve Romano, M.D.
Pfizer, Inc.
Jerrold Rosenbaum, M.D.
Massachusetts General Hospital
Neil Ryan, M.D.
University of Pittsburgh School of Medicine
Martha Sajatovic, M.D.
University Hospitals Case Medical Center
Bruce Saltz, M.D., P.A.
Mental Health Advocates, Inc.
Richard Shelton, M.D.
University of Alabama at Birmingham
«New Investigator Alumni
s Representing
18
ASCP CME Committee
Acknowledgements
Program Committee (continued)
«Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine
Benedetto Vitiello, M.D.
National Institute of Mental Health
Karen Wagner, M.D.
University of Texas, Galveston (ASCP Board Member)
«Janet Williams, D.S.W.
MedAvante
«Kimberly Yonkers, M.D.
Yale School of Medicine
«Carlos A. Zarate, M.D.
National Institute of Mental Health
New Investigator Award Committee
«Christoph U. Correll, M.D.
The Zucker Hillside Hospital
«Lori Davis, M.D.
Tuscaloosa VA Medical Center
«Tiffany Farchione, M.D.
Food and Drug Administration
Lindsey Grandison, Ph.D.
National Institute on Alcohol Abuse and Alcoholism
Lauren D. Hill, Ph.D.
National Institute of Mental Health
Bruce Kinon, M.D.
Eli Lilly & Company
Ivan Montoya, M.D., MPH
National Institute on Drug Abuse
«Katharine Phillips, M.D.
Rhode Island Hospital/Brown University
s
Mark H. Rapaport, M.D.
Emory University School of Medicine (ASCP Board Member)
Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center
«Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine
«New Investigator Alumni
s Representing
19
ASCP CME Committee
Acknowledgements
ASCP Officers and Board
Maurizio Fava, M.D. – ASCP President
Massachusetts General Hospital
s
Mark H. Rapaport, M.D. – ASCP Treasurer
Emory University School of Medicine
Leslie Citrome, M.D., M.P.H.
New York Medical College
«Christoph U. Correll, M.D.
The Zucker Hillside Hospital
«Kristina Deligiannidis, M.D.
University of Massachusetts Medical School
Marlene Freeman, M.D.
Massachusetts General Hospital
Alan Gelenberg, M.D.
Penn State University
Ira Glick, M.D.
Stanford University School of Medicine
s
Joseph Goldberg, M.D.
Mount Sinai School of Medicine
John Kane, M.D.
The Zucker Hillside Hospital
Arif Khan, M.D.
Duke University School of Medicine
John Newcomer, M.D.
Leonard M. Miller School of Medicine, University of Miami
Michael Thase, M.D.
University of Pennsylvania
Karen Wagner, M.D., Ph.D.
University of Texas Medical Branch
Sidney Zisook, M.D.
University of California, San Diego
«New Investigator Alumni
s Representing
20
ASCP CME Committee
Meeting Announcements
Meeting Services
Registration Desk Hours:
Sunday
10:00 am – 5:00 pm
Monday
7:30 am – 6:30 pm
Tuesday
7:30 am – 6:45 pm
Wednesday
7:30 am – 6:00 pm
Thursday
7:30 am – 12:00 pm
*The registration/meeting information desk is located at the main entrance of the
Grand Ballroom.
The Computer Center is open on the below dates and times for attendees
to briefly check emails. The Computer Center is located in the Foyer of
Diplomat 1-2. Hours:
Sunday
12:00 pm – 5:00 pm
Monday
8:00 am – 6:00 pm
Tuesday – Wednesday
7:30 am – 6:30 pm
Thursday
7:30 am – 12:00 pm
Americans with Disabilities Act - It is the policy of ASCP not to discriminate
against any person on the basis of disabilities. If you feel you need services or
auxiliary aids mentioned in this act in order to fully participate in this continuing
education activity, please call the Executive Office at 615-649-3085 or send an
email to info@ascpp.org.
Job Announcements may be posted on a message board at the ASCP
registration desk.
Discounts – All ASCP Annual Meeting attendees who booked their room at the
Westin Diplomat through the ASCP meeting website will have the following resort
amenities.
• Access to Standard high-speed internet in the guest rooms for $6 per day
• Fitness Center admittance
• Daily newspaper
• In-room coffee and tea
21
Meeting
Announcements
The ASCP Speaker Ready Room is open on the below dates and times for
presenters to upload slides. The meeting organizers ask that all speakers
upload their slides 24 hours prior to their scheduled presentation time.
The Speaker Ready Room is located in Diplomat 3. Hours:
Sunday
12:00 pm – 5:00 pm
Monday
8:00 am – 6:00 pm
Tuesday – Wednesday
7:30 am – 6:30 pm
Thursday
7:30 am – 12:00 pm
Meeting Announcements
Continuing Education Credits
Disclosures are available for all ASCP Annual Meeting presenters online
at www.ASCPMeeting.org.
Continuing Education Credits are available for physicians, pharmacists,
psychologists and social workers. Applications for credit must be completed
online with the meeting evaluation survey. The survey may be completed
in the ASCP Computer Center in the Foyer of Diplomat 1-2 or after the
conference at www.ASCPMeeting.org. Surveys for continuing education
credit must be submitted no later than July 18, 2014. There is a $40.00
administrative fee for CME/CE applications. It is the policy of the ASCP
to require disclosure of financial relationships from individuals in a position
to control the content of a CME activity; to identify and resolve conflicts of
interest related to those relationships; and to make disclosure information
available to the audience prior to the CME activity. Presenters are required to
disclose discussions of unlabeled/unapproved uses of drugs or devices during
their presentations.
Physicians
The American Society for Clinical
Psychopharmacology (ASCP) designates this
live meeting for a maximum of 21.5 AMA PRA
Category 1 Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Pharmacists
USF Health is accredited by the Accreditation Council for
Pharmacy Education as a provider of continuing pharmacy
education. This knowledge-based program has been approved
for 21.5 contact hours. Universal program number is as follows:
0230-9999-14-0130-L01-P.
To receive continuing education credit, a pharmacist must attend the
accredited sessions, actively participate in questions and answers and must
return the program evaluation instrument. In order to receive full credit,
registrants must arrive no later than 10 minutes after the start of the meeting
and must attend the entire meeting.
22
Meeting Announcements
Psychologists
USF Health is approved by the American Psychological
Association to sponsor continuing education for
psychologists. USF Health maintains responsibility for this
program and its content. This activity has been approved
for 21.5 CE credits. Full attendance of the live activity is
required. Partial credit will not be awarded.
Social Workers
USF Health is an approved provider (BAP #433 – exp.
3/31/15) of continuing education credits for clinical
social work, marriage and family therapy, and mental
health counseling. This program has been reviewed and
approved for 25.8 credit hours, 50-minute contact hours.
All participants who request continuing education credits by July 18, 2014,
should expect to receive their statement of credits via email in late August.
The Meeting Evaluation Survey will be available at www.ASCPMeeting.org.
We encourage all registrants to complete the evaluation. Attendees
requesting CME or CE credits must complete the survey in order to obtain
credits. There is a $40.00 administrative fee for CME/CE applications. Your
candid input on the 2014 meeting is appreciated as we strive to improve the
meeting each year.
ASCP Meeting Support – The 2014 ASCP Annual Meeting receives no
corporate funding.
2015 ASCP Annual Meeting
The 2015 ASCP Annual Meeting will take place June 22-25, 2015 at the Loews
Miami Beach Hotel in Miami, Florida. Details regarding abstract submission
for the 2015 Meeting will be released in September, 2014.
23
Notes
24
Sunday, June 15, 2014
8:30am – 4:30pm
Co-Chairs:
New Investigator Workshop (Invitation Only)
Regency 1
Mark H. Rapaport, M.D., Emory University School of Medicine
Lauren D. Hill, Ph.D., National Institute of Mental Health
The ASCP Annual Meeting offers a special program for New Investigators
in an effort to promote the education and training of junior investigators in
psychopharmacology. Established investigators were asked to nominate
individuals who may be interested in a research career in psychopharmacology
for this special program. These nominees submitted an abstract describing their
current research or area of research interest, a letter of recommendation from
their chair or mentor, a career statement and a curriculum vitae. The selection
of awardees was based upon the scientific merit of the abstract, the level of
training of the nominee and a committee of internal and external reviewers’
assessment of the relative value of the specialized program to each applicant
at this time in his/her career. The awardees will participate in this special
educational workshop and present their posters during the scheduled poster
sessions. In addition, they will receive a travel expense award and a certificate
acknowledging their participation in the program at an award ceremony on
Monday evening, June 16, 2014. This year’s 20 New Investigator awardees are
indicated with a ribbon in the poster section of this program.
Faculty
Katharine Phillips, M.D.
Rhode Island Hospital/Brown University
Christoph U. Correll, M.D.
The Zucker Hillside Hospital
A. John Rush, M.D.
Duke-National University of Singapore
Lori Davis, M.D.
Tuscaloosa VA Medical Center
Nina R. Schooler, Ph.D.
State University of New York,
Downstate Medical Center
Lindsey Grandison, Ph.D.
National Institute on Alcohol Abuse
and Alcoholism
Lauren Hill, Ph.D. – Chair
National Institute of Mental Health
Holly Swartz, M.D.
University of Pittsburgh School of
Medicine
Tiffany Farchione, M.D.
Food and Drug Administration
Special thanks to the ASCP New Investigator Program supporters:
• Otsuka Pharmaceuticals, Inc.
• Pharmaceutical Product Development (PPD)
25
Sunday
Mark Bunker, Pharm.D.
Cyberonics, Inc.
Sunday, June 15, 2014
2014 New Investigator Awardees
Eric Achytes, M.D., M.S.
Michigan State University College of
Human Medicine
Kamilla Miskowiak, Ph.D.
Psychiatric Center Copenhagen,
Copenhagen University Hospital
Ana Andreazza, Ph.D.
University of Toronto, Departments of
Pharmacology and Psychiatry
Mark Niciu, M.D., Ph.D.
National Institutes of Health (NIH)/
National Institute of Mental Health
(NIMH)
Shinichiro Nakajima, M.D., Ph.D.
Centre for Addiction and Mental Health
Hidehiro Oshibuchi, M.D., Ph.D.
Department of Psychiatry, University of
California, San Francisco
Chaya Bhuvaneswaran, M.D., MPH
Department of Psychiatry, University of
Massachusetts-Worcester
Kyle Burghardt, Pharm.D.
University of Michigan College of
Pharmacy
M. Mercedes Perez-Rodriguez, M.D.,
Ph.D.
Icahn School of Medicine at Mount
Sinai and MIRECC at James J Peters
VAMC
Joan Camprodon, M.D., Ph.D., MPH
Massachusetts General Hospital,
Harvard Medical School
Donna Roybal, M.D.
University of Texas Health Sciences
Center at San Antonio
Michael Davis, M.D., Ph.D.
VA Greater Los Angeles; University of
California Los Angeles
Diana Simeonova, Dipl. Psych.,
Ph.D.
Emory University School of Medicine
Stephanie Duhoux, Ph.D.
Icahn School of Medicine at Mount
Sinai
Nhi-Ha Trinh, M.D., MPH
Depression Clinical and Research
Program, Massachusetts General
Hospital
Jennifer Felger, Ph.D.
Emory University School of Medicine
Gwyneth Zai, M.D., FRCPC, MSc
Neurogenetics Section and
Department of Psychiatry, Centre
for Addiction and Mental Health,
University of Toronto
Philip Gerretsen, M.D., MSW
Centre for Addiction and Mental Health
Aaron Koenig, M.D.
Western Psychiatric Institute & Clinic
Clement Zai, Ph.D.
Centre for Addiction and Mental Health
26
Monday, June 16, 2014
AT-A-GLANGE
Monday, June 16, 2014
7:30am – 8:30am
NIA Breakfast Roundtable (Invitation only)
Room 216
8:30am – 9:00am
Conference Opening
Grand Ballroom
9:00am – 10:30am
Panel Sessions
*Recognizing
and Treating
Catatonia across
the Diagnostic
Spectrum:
The Impact of
New DSM-5
Classification
Risks Posed
by Duplicate or
Inappropriate
Subjects in
Clinical Trials
and Methods for
Mitigating the
Risk
Research Forum:
Meditative
Practices,
Underlying
Neurobiological
Mechanisms, and
Application to
Mental Health
*Biological
Approaches To
Treat Substances
Use Disorders
Location:
Diplomat 1-2
Location:
Atlantic 1
Location:
Atlantic 2
Location:
Atlantic 3
10:30am – 10:45am
Break
Ballroom Foyers
10:45am – 12:15pm
Panel Sessions
*Novel
Treatments in
Bipolar Disorder:
Primary and
Secondary
Targets
Dimensional
Symptom
and Disability
Measures in
DSM-5
*Weighing In on
Relative Risks of
Fetal Exposure
to Psychotropics
and Psychiatric
Disorders
Location:
Diplomat 1-2
Location:
Atlantic 1
Location:
Atlantic 2
Location:
Atlantic 3
*of special interest to clinicians
27
Monday
NIAAA
Sponsored
ACTIVE Update:
Missing Data
in Alcohol Use
Disorder Clinical
Trials - Issues
and Analytic
Methods
Monday, June 16, 2014
12:15pm – 2:00pm
Lunch On Own
1:00pm – 2:00pm
First Time Attendee Meet & Greet
Atlantic 1
2:00pm – 4:00pm
Pharmaceutical Pipeline Presentations
Grand Ballroom
4:00pm – 4:15pm
Break
Ballroom Foyers
4:15pm – 5:45pm
Panel Sessions
Placebo
Response,
Response
Variance and
Antidepressantplacebo
Differences
in Recent
Antidepressant
Clinical Trials
based on Three
Patient Interview
Models
*Bipolar CHOICE
(Clinical Health
Outcomes
Initiative in
Comparative
Effectiveness):
A Pragmatic
Trial of Lithium
vs. a Second
Generation
Antipsychotic for
Bipolar Disorder
*NIAAA Panel
Session:
Advances in
Treatments
for PTSD
and Alcohol
Comorbidity
Novel and
Underutilized
Strategies
to Improve
Adherence
and Reduce
Relapse Risk in
Schizophrenia
Location:
Diplomat 1-2
Location:
Atlantic 1
Location:
Atlantic 2
Location:
Atlantic 3
6:15pm – 7:45pm
New Investigators’ Award Ceremony & Reception
(Invitation only)
Diplomat 4-5
*of special interest to clinicians
28
Monday, June 16, 2014
FULL SCHEDULE
Monday, June 16, 2014
7:30am – 8:30am
NIA Breakfast Roundtable (Invitation only)
Room 216
8:30am – 9:00am
Conference Opening
Grand Ballroom
Panel Sessions
9:00am – 10:30am
*Recognizing and Treating Catatonia across the
Diagnostic Spectrum: The Impact of New DSM-5
Classification
Diplomat 1-2
Chair & Discussant: Georgios Petrides, The Zucker Hillside Hospital
9:00am – 9:10am
Introduction
9:10am – 9:30am
Catatonia: Video Workshop on Recognition and
Management
Andrew Francis, SUNY Stony Brook
9:30am – 9:50am
Pediatric Catatonia: Review and New Vagal Theory
Dirk M. Dhossche, University of Mississippi Medical
Center
9:50am – 10:10am
Longitudinal Assessment of the Psychomotor
Dimension in Psychosis: Implications for
Treatment
Stanley N. Caroff, Philadelphia VA Medical Center/
University of Pennsylvania
10:10am – 10:30am
Discussion
*of special interest to clinicians
29
Monday, June 16, 2014
9:00am – 10:30am
Risks Posed by Duplicate or Inappropriate
Subjects in Clinical Trials and Methods for
Mitigating the Risk
Atlantic 1
Chair: Jonathan Rabinowitz, Bar Ilan University
Discussant: Janet Williams, MedAvante, Inc.
9:00am – 9:10am
Introduction
9:10am – 9:30am
Evidence and Risks of Duplicate Subjects in
Clinical Trials and How You Can Minimize the Risk
Jonathan Rabinowitz, Bar Ilan University
9:30am – 9:50am
The Professional Patient ‘Spectrum’ or Simply
Inappropriate Patients: 50 Shades of Grey in
Protocol Non-adherence
Michael Detke, Indiana University
Proven Strategies to Mitigate the Risk of Enrolling
Professional Subjects in Large Depression Studies
Brooke Geibel, Shire
10:10am – 10:30am
Discussion
9:00am – 10:30am
Research Forum: Meditative Practices, Underlying
Neurobiological Mechanisms, and Application to
Mental Health
Atlantic 2
9:50am – 10:10am
Chair: Emmeline Edwards, NIH/NCCAM
Co-chair: Kristen Huntley, NIH/NCCAM
Discussant: David Shurtleff, NIH/NCCAM
9:00am – 9:10am
Introduction
9:10am – 9:30am
Neuroimaging as a Tool for the Study of Meditation
Kelvin O. Lim, University of Minnesota
9:30am – 9:50am
What is Known about the Effectiveness of
Meditative Approaches for Resilience and
Cognitive Enhancement?
Amishi Jha, University of Miami
30
Monday, June 16, 2014
9:00am – 10:30am
(continued)
Research Forum: Meditative Practices, Underlying
Neurobiological Mechanisms, and Application to
Mental Health
Atlantic 2
9:50am – 10:10am
Innovation and Opportunities in Neuroscientific
Research on Meditation
Richard J. Davidson, University of Wisconsin
10:10am – 10:30am
Discussion
9:00am – 10:30am
*Biological Approaches to Treat Substances Use
Disorders
Atlantic 3
Chair: Phil Skolnick, NIDA/NIH
Discussant: Raye Litten, NIAAA
9:00am – 9:10am
Introduction
9:10am – 9:25am
Genetically Engineered Butyrylcholinesterase
(TV-1380): An Innovative Approach to Treat
Cocaine Dependence
Phil Skolnick, NIDA/NIH
9:25am – 9:40am
Use of Functional Assays to Develop a Novel Antinicotine Vaccine
Heather L. Davis, Pfizer Vaccine Immunotherapeutics
9:40am – 9:55am
Development of a Heroin Vaccine
Gary R. Matyas, Walter Reed Army Institute of
Research
9:55am – 10:10am
Continuing Towards Gene Transfer of Modified
Human Butyrylcholinesterase to Treat Cocaine
Addiction
Stephen Brimijoin, Mayo Clinic
10:10am – 10:30am
Discussion
10:30am – 10:45am
Break
Ballroom Foyers
*of special interest to clinicians
31
Monday, June 16, 2014
Panel Sessions
10:45am – 12:15pm
NIAAA Sponsored ACTIVE Update: Missing Data
in Alcohol Use Disorder Clinical Trials - Issues and
Analytic Methods
Diplomat 1-2
Chair: Raymond F. Anton, Medical University of South Carolina
Discussant: Raye Z. Litten, NIAAA
10:45am – 10:55am
Introduction
10:55am – 11:10am
Overview of the ACTIVE Workgroup and Mission
and Importance of Missing Drinking Data in
Alcohol Use Disorder Trials
Raymond F. Anton, Medical University of South
Carolina
11:10am – 11:25am
11:25am – 11:40am
How Does Drinking Change When People
Stop Taking Medicines During a Clinical Trial?
Implications for Missing Drinking Data Reduction
and Imputation
Robert L. Stout, Pacific Institute for Research and
Evaluation
The Use of Pattern Mixture Models for Imputation
and Analysis of Missing Drinking Data in Nalmfene
Trials for Alcohol Dependence During Regulatory
Approval in Europe
Per Sorensen, H. Lundbeck A/S
Validity of Various Missing Drinking Data
Imputation Methods – Results from Re-analysis of
the US COMBINE Study
Katie Witkiewitz, University of New Mexico
11:55am – 12:15pm
Discussion
11:40am – 11:55am
32
Monday, June 16, 2014
10:45am – 12:15pm
*Novel Treatments in Bipolar Disorder: Primary and
Secondary Targets
Atlantic 1
Chair: Katherine Burdick, Mount Sinai School of Medicine
Discussant: Terence Ketter, Stanford University School of Medicine
10:45am – 10:55am
Introduction
10:55am – 11:10am
Methodological Considerations in the Design and
Conduct of Acute Adjunctive Bipolar Depression
Treatment Trials
Joseph R. Calabrese, Case Western Reserve School
of Medicine
11:10am – 11:25am
11:25am – 11:40am
11:40am – 11:55am
Effect of Lurasidone on Cognitive Impairment:
From the Lab to the Clinic
Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
Methodological Challenges to Cognitive Trials in
Bipolar Disorder
Katherine Burdick, Mount Sinai School of Medicine
Interaction Effects between Affective Symptoms
and Cognitive Function in Bipolar Disorder Clinical
Trials
Joseph F. Goldberg, Icahn School of Medicine at
Mount Sinai
11:55am – 12:15pm
Discussion
10:45am – 12:15pm
Dimensional Symptom and Disability Measures in
DSM-5
Atlantic 2
Chair: William Narrow, American Psychiatric Association
Discussant: Lori Davis, Tuscaloosa VA Medical Center and University of
Alabama School of Medicine
10:45am – 10:55am
Introduction
10:55am – 11:15am
DSM-5 Cross-cutting Dimensional Measures:
Reliability, Sensitivity to Change, and Association
with Disability
Diana E. Clarke, American Psychiatric Association
*of special interest to clinicians
33
Monday, June 16, 2014
10:45am – 12:15pm Dimensional Symptom and Disability Measures in
(continued)DSM-5
Atlantic 2
11:15am – 11:35am
DSM-5 Dimensional Symptom and Disability
Measures in Routine Clinical Practice Settings
Eve K. Mościcki, American Psychiatric Association
The World Health Organization Disability
Assessment Schedule in the DSM-5 Field Trials:
Associations with Psychiatric Diagnosis
William Narrow, American Psychiatric Association
11:55am – 12:15pm
Discussion
10:45am – 12:15pm
*Weighing In on Relative Risks of Fetal Exposure
to Psychotropics and Psychiatric Disorders
Atlantic 3
11:35am – 11:55am
Chair: Lee S. Cohen, Massachusetts General Hospital
Co-chair & Discussant: Marlene Freeman, Massachusetts General Hospital
10:45am – 10:55am
Introduction
10:55am – 11:15am
The National Pregnancy Registry for Atypical
Antipsychotics: Effects of Fetal Exposure on Risk
for Congenital Malformations and Maternal and
Newborn Outcomes
Lee S. Cohen, Massachusetts General Hospital
11:15am – 11:35am
11:35am – 11:55am
Prenatal Exposure to SSRIs: Sorting the Evergrowing Data
Sonia Hernandez-Diaz, Harvard School of Public
Health
Impact of Maternal Psychiatric Illness on Fetal,
Obstetrical and Neonatal Wellbeing
Margaret Altemus, Weill Medical College, Cornell
University
11:55am – 12:15pm
Discussion
12:15pm – 2:00pm
Lunch On Own
1:00pm – 2:00pm
First Time Attendee Meet & Greet
Atlantic 1
*of special interest to clinicians
34
Monday, June 16, 2014
2:00pm – 4:00pm
Pharmaceutical Pipeline Presentations
Grand Ballroom
Chair: Carlos Zarate, National Institute of Mental Health
2:00pm – 2:10pm
2:10pm – 2:20pm
2:20pm – 2:30pm
2:30pm – 2:40pm
2:40pm – 2:50pm
2:50pm – 3:00pm
3:00pm – 3:10pm
A Pilot Study of a Novel Monoamine Triple
Reuptake Inhibitor EB-1020 SR in the Treatment of
ADHD in Adults
Timothy Wilens, Massachusetts General Hospital
Metadoxine Extended Release (MDX): A Novel
Drug Candidate for the Treatment of ADHD &
Other Cognitive Disorders
Jonathan Rubin, Alcobra Pharma
A Rapidly Acting Intranasal Treatment for the
Symptoms of GAD
Michael R. Liebowitz, Pherin Pharmaceuticals
Lupron in Combination with an
Acetylcholinesterase Inhibitor Halts Cognitive
Decline in Women with Alzheimer’s Disease over a
48 Week Period
Richard Bowen, OTB Research
Efficacy and Safety of a Novel mGlu2 Receptor
Positive Allosteric Modulator as an Adjunctive
Treatment to an SSRI/SNRI in the Treatment of
Anxious Depression
Justine Kent, Janssen
A Double-blind, Randomized, Placebo-controlled,
Parallel Group, Dose Frequency Study of
Intravenous Ketamine in Patients with Treatmentresistant Depression
Jaskaran Singh, Janssen Research and Development,
LLC
Randomized, Double-blind, Active-controlled,
Phase 2/3 Study to Determine the Short-term
(6-Week) and Long-term (6 Month) Cognitive and
Anti-psychotic Efficacy, Safety and Tolerability of
CYP-1020 Compared to Risperidone
Jonathan Rabinowitz, Bar Ilan University
35
Monday, June 16, 2014
2:00pm – 4:00pm
(continued)
Pharmaceutical Pipeline Presentations
Grand Ballroom
3:10pm – 3:20pm
Results of a Phase 2B Clinical Trial of TC-5619,
a Selective Alpha 7 Neuronal Nicotinic Receptor
(NNR) Agonist in the Adjunctive Treatment of
Negative Symptoms and Cognitive Dysfunction in
Schizophrenia
David Hosford, Targacept, Inc.
3:20pm – 3:30pm
AZD8529, a Positive Allosteric Modulator of
the mGluR2 Receptor for the Treatment of
Schizophrenia
Alan Cross, AstraZeneca Neuroscience Innovative
Medicines Unit
Advancing ITI-007: A Novel Product Candidate for
the Treatment of Schizophrenia, Bipolar Disorder
and Other Neuropsychiatric Indications
Kimberly E. Vanover, Intra-Cellular Therapies, Inc.
4:00pm – 4:15pm
Break
Ballroom Foyers
3:30pm – 3:40pm
Panel Sessions
4:15pm – 5:45pm
Placebo Response, Response Variance and
Antidepressant-placebo Differences in Recent
Antidepressant Clinical Trials Based on Three
Patient Interview Models
Diplomat 1-2
Chair: Arif Khan, Northwest Clinical Research Center
Discussant: Walter Brown, Brown University
4:15pm – 4:25pm
Introduction
4:25pm – 4:45pm
Examining the Utility and Futility of Surveillance
Strategies for CNS Trials
Steven D. Targum, Clintara, LLC
36
Monday, June 16, 2014
4:15pm – 5:45pm
(continued)
Placebo Response, Response Variance and
Antidepressant-placebo Differences in Recent
Antidepressant Clinical Trials Based on Three
Patient Interview Models
Diplomat 1-2
4:45pm – 5:05pm
The Use of Blinded, Independent, Remote Ratings
in Psychiatric Clinical Trials: The Good, the Bad,
and the Appropriate Situation
Michael Detke, Indiana University
Magnitude of Placebo Response and Response
Variance in Antidepressant Clinical Trials using
Enhanced Interviews Techniques Compared to
Traditional Rating Interviews
Arif Khan, Northwest Clinical Research Center
5:25pm – 5:45pm
Discussion
4:15pm – 5:45pm
*Bipolar CHOICE (Clinical Health Outcomes
Initiative in Comparative Effectiveness): A
Pragmatic Trial of Lithium vs. a Second Generation
Antipsychotic for Bipolar Disorder
Atlantic 1
5:05pm – 5:25pm
Chair: Terence Ketter, Stanford University School of Medicine
Co-chair: Andrew Nierenberg, Massachusetts General Hospital
Discussant: Mauricio Tohen, University of New Mexico
4:15pm – 4:25pm
Introduction
4:25pm – 4:45pm
4:45pm – 5:05pm
Bipolar CHOICE (Clinical Health Outcomes
Initiative in Comparative Effectiveness): Rationale,
Design, and Demographics
Edward S. Friedman, University of Pittsburgh School
of Medicine
Bipolar CHOICE (Clinical Health Outcomes
Initiative in Comparative Effectiveness)
Andrew Nierenberg, Massachusetts General Hospital
*of special interest to clinicians
37
Monday, June 16, 2014
4:15pm – 5:45pm
(continued)
*Bipolar CHOICE (Clinical Health Outcomes
Initiative in Comparative Effectiveness): A
Pragmatic Trial of Lithium vs. a Second Generation
Antipsychotic for Bipolar Disorder
Atlantic 1
5:05pm – 5:25pm
Bipolar CHOICE Safety and Tolerability Outcomes:
Focus on Obesity and Cardiometabolic Health
David Kemp, Case Western Reserve University
5:25pm – 5:45pm
Discussion
4:15pm – 5:45pm
*NIAAA Panel Session: Advances in Treatments for
PTSD and Alcohol Comorbidity
Atlantic 2
Chair: Raye Z. Litten, NIAAA
Co-chair: Ismene L. Petrakis, Yale University School of Medicine
Discussant: Raye Z. Litten, NIAAA
4:15pm – 4:25pm
Introduction
4:25pm – 4:45pm
Pharmacotherapy of Patients with Post Traumatic
Stress Disorder (PTSD) and Comorbid Alcohol Use
Disorders among Veterans
Ismene L. Petrakis, Yale University School of Medicine
4:45pm – 5:05pm
Prazosin for Comorbid PTSD and Alcohol
Dependence: A Pilot Randomized Clinical Trial
Tracy Simpson, VA Puget Sound Health Care System
Effective Treatment Strategies for Patients with
Concurrent PTSD and Addiction
David Oslin, University of Pennsylvania
5:25pm – 5:45pm
Discussion
5:05pm – 5:25pm
*of special interest to clinicians
38
Monday, June 16, 2014
4:15pm – 5:45pm
Novel and Underutilized Strategies to Improve
Adherence and Reduce Relapse Risk in
Schizophrenia
Atlantic 3
Chair: Christoph Correll, The Zucker Hillside Hospital
Discussant: Nina R. Schooler, SUNY Downstate Medical Center
4:15pm – 4:25pm
Introduction
4:25pm – 4:40pm
Response, Remission and Recovery in
Schizophrenia
John M. Kane, The Zucker Hillside Hospital
4:40pm – 4:55pm
4:55pm – 5:10pm
Effect of Trial Design, Population and Illness
Phase on the Role of Long-acting Injectable
Antipsychotics for Signaling and Preventing
Non-adherence in Schizophrenia
Christoph Correll, The Zucker Hillside Hospital
Leveraging Novel Technologies to Enhance
Adherence
Adam Hanina, Ai Cure Technologies
Technology-based Approaches for the Detection
and Prevention of Relapse in Schizophrenia
Dror Ben-Zeev, Dartmouth College
5:25pm – 5:45pm
Discussion
6:15pm – 7:45pm
New Investigators’ Award Ceremony & Reception
(Invitation only)
Diplomat 4-5
5:10pm – 5:25pm
39
Notes
40
Tuesday, June 17, 2014
Tuesday
AT-A-GLANCE
Tuesday, June 17, 2014
6:45am – 8:00am
15th Annual Fun Run/Walk
Meet in Main Lobby
7:00am – 8:30am
ASCP Board Meeting (Invitation only)
Room 217
7:30am – 8:30am
NIA Breakfast Roundtable (Invitation only)
Room 216
7:30am – 9:00am
Morning Break
Ballroom Foyers
8:30am – 10:00am
Regulatory Plenary: FDA Science Initiatives:
A Brief Update
Grand Ballroom
10:00am – 10:15amBreak
Ballroom Foyers
ASCP Lifetime Awardee Presentation – A. John
Rush: Bridging the Chasm between Research and
Practice
Grand Ballroom
11:15am – 1:00pm
Poster Session I with Lunch
Regency Ballroom
1:15pm – 2:45pm
Panel Sessions
10:15am – 11:15am
*Overcoming the
Shortcomings
of Treatment
Practice
Guidelines
for Mood and
Psychotic
Disorders
NIMH/NCCAM
Panel: Conducting
Pragmatic Trials
in Mental Health:
Lessons Learned
from the NIH
Health Care
Systems Research
Collaboratory
Inflammation
and Insulin
Resistance:
Implications for
Pathophysiology
and Treatment
*Long Acting
Injectable
Antipsychotics:
Perspectives
on their Role in
Schizophrenia
Treatment
Location:
Diplomat 1-2
Location:
Atlantic 1
Location:
Atlantic 2
Location:
Atlantic 3
*of special interest to clinicians
41
Tuesday, June 17, 2014
ASCP Business Meeting (ASCP Members Only)
Grand Ballroom
2:45pm – 3:15pm
3:15pm – 3:30pmBreak
Ballroom Foyers
Individual Research Reports
3:30pm – 4:30pm
Anxiety Disorder
Presentations
Depression
Presentations
Schizophrenia
and Bipolar
Disorder
Presentations
Statistical
Methods,
Personality
Disorders,
Substance
Abuse, and
Comorbidity
Presentations
Location:
Diplomat 1-2
Location:
Atlantic 1
Location:
Atlantic 2
Location:
Atlantic 3
4:30pm – 4:45pmBreak
Ballroom Foyers
4:45pm – 6:45pm
Workshops
Cognitive Deficits
in Depression:
What are They? Are
They Independent
Dimensions? Are They
Targets for Treatment?
*Psychopharmacology
of Residual Symptoms
in Mood Disorders and
Schizophrenia
New Approaches to
Funding Clinical Trials
at NIMH
Location: Atlantic 1
Location: Atlantic 2
Location: Atlantic 3
7:00pm – 8:00pm
ASCP Reception
South Palm Court
9:00pm – 12:00am
Black & White Affair, hosted by Zane Courbay
Room 3641
*of special interest to clinicians
42
Tuesday, June 17, 2014
FULL SCHEDULE
Tuesday, June 17, 2014
6:45am – 8:00am
15th Annual Fun Run/Walk
Meet in Main Lobby
7:00am – 8:30am
ASCP Board Meeting (Invitation only)
Room 217
7:30am – 8:30am
NIA Breakfast Roundtable (Invitation only)
Room 216
7:30am – 9:00am
Morning Break
Ballroom Foyers
8:30am – 10:00am
Regulatory Plenary: FDA Science Initiatives:
A Brief Update
Grand Ballroom
Chair: Ni A. Khin, M.D., U.S. Food and Drug Administration
This session will provide updates on regulatory
initiatives from the US Food and Drug Administration
(FDA). Dr. Ni Khin will give a brief overview of the joint
FDA initiative with European Medicines Agency (EMA)
to ensure data quality in clinical trials and good clinical
practice compliance. Dr. Celia Winchell from FDA’s
Division of Anesthesia and Analgesia Products (DAAP)
will discuss the challenges of determining efficacy
endpoints in clinical trials for addiction treatment drugs.
Specifically, she will discuss how DAAP identified a
pattern of alcohol use as an alternative endpoint to
complete abstinence based on recent analyses of data.
Dr. Silvana Borges from FDA’s Division of Psychiatry
Products will present preliminary findings regarding
use of active controls in depression trials. There will
be an informal discussion with the audience on these
selected topics as well as other regulatory issues of
common interest within this context.
8:30am – 8:45am
Ni A. Khin, M.D., Food and Drug Administration
8:45am – 9:05am
Celia Winchell, M.D., Food and Drug Administration
9:05am – 9:25am
Silvana Borges, M.D., Food and Drug Administration
9:25am – 10:00am
Panel Discussion and Q&A
43
Tuesday, June 17, 2014
10:00am – 10:15am
Break
Ballroom Foyers
10:15am – 11:15am
ASCP Lifetime Awardee Presentation – A. John
Rush: Bridging the Chasm between Research and
Practice
Grand Ballroom
Patient centered research and comparative
effectiveness research address practical issues that
aim at addressing patients’ concerns or choices
among treatments, respectively. In addition to
these important objectives, clinicians need to better
understand how to deliver each treatment; to whom
to deliver (or not) particular treatments; when to
discontinue, switch, or augment a specific treatment;
and for whom which specific treatment sequences
are indicated. This presentation discusses practical,
simple, efficient research design, measurement and
analytic options, that could address these important
clinical knowledge gaps with the aim of improving
patient outcomes and treatment cost efficiencies.
11:15am – 1:00pm
Poster Session I with Lunch
Regency Ballroom
*See Pages 69 through 80 for poster listing.
Panel Sessions
1:15pm – 2:45pm
*Overcoming the Shortcomings of Treatment
Practice Guidelines for Mood and Psychotic
Disorders
Diplomat 1-2
Chair: Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai
Discussant: Michael E. Thase, Perelman School of Medicine of the University
of Pennsylvania
1:15pm – 1:25pm
Introduction
1:25pm – 1:45pm
Practice Guidelines for Bipolar Disorder: What’s
Useful, What’s Not, and What’s Missing
Joseph F. Goldberg, Icahn School of Medicine at
Mount Sinai
*of special interest to clinicians
44
Tuesday, June 17, 2014
1:15pm – 2:45pm
(continued)
*Overcoming the Shortcomings of Treatment
Practice Guidelines for Mood and Psychotic
Disorders
Diplomat 1-2
1:45pm – 2:05pm
Treatment Guidelines for MDD: Evidence-based,
Eminence-based, or Faith-based?
Alan J. Gelenberg, Penn State College of Medicine
Practice Guidelines for Treatment of
Schizophrenia: Consensus or Confusion?
Peter J. Weiden, UIC Medical Center
2:25pm – 2:45pm
Discussion
1:15pm – 2:45pm
NIMH/NCCAM Panel: Conducting Pragmatic Trials
in Mental Health: Lessons Learned from the NIH
Health Care Systems Research Collaboratory
Atlantic 1
2:05pm – 2:25pm
Chair & Discussant: Emmeline Edwards, NIH, NCCAM
Co-chair: Wendy Weber, NIH, NCCAM
1:15pm – 1:25pm
Introduction
1:25pm – 1:45pm
Conducting Pragmatic Trials in Mental Health:
Lessons Learned from the NIH Health Care
Systems Research Collaboratory
Wendy Weber, NIH, NCCAM
1:45pm – 2:05pm
Pragmatic Trial of Population-based Program to
Prevent Suicide Attempts
Greg Simon, Group Health Research Institute
NIMH/NCCAM Panel: Conducting Pragmatic Trials
in Mental Health: Lessons Learned from the NIH
Health Care Systems Research Collaboratory
Liz Delong, Duke University Medical Center
2:25pm – 2:45pm
Discussion
2:05pm – 2:25pm
*of special interest to clinicians
45
Tuesday, June 17, 2014
1:15pm – 2:45pm
Inflammation and Insulin Resistance: Implications
for Pathophysiology and Treatment
Atlantic 2
Chair: David Kemp, Case Western Reserve University
Discussant: Madhukar Trivedi, UT Southwestern
1:15pm – 1:20pm
Introduction
1:20pm – 1:35pm
PPAR-γ Agonism as a Modulator of Mood: Proofof-concept for Pioglitazone in Bipolar Depression
David Kemp, Case Western Reserve University
1:35pm – 1:50pm
1:50pm – 2:05pm
Association between Kynurenine-pathway
Metabolites and Gray Matter Volumes of the
Hippocampus and Amygdala in Patients with Mood
Disorders
Jonathan Savitz, Laureate Institute for Brain Research
Trait and State Patterns of Inflammatory
Biomarkers in Bipolar Disorder
Jess G. Fiedorowicz, University of Iowa
2:05pm – 2:20pm
Biomarkers of Illness Activity in Bipolar Disorder
Flavio Kapczinski, Federal University of Rio Grande do
Sul
2:20pm – 2:45pm
Discussion
1:15pm – 2:45pm
*Long Acting Injectable Antipsychotics:
Perspectives on their Role in Schizophrenia
Treatment
Atlantic 3
Chair: Nina R. Schooler, SUNY Downstate Medical Center
Discussant: John M. Kane, The Zucker Hillside Hospital
1:15pm – 1:25pm
Introduction
1:25pm – 1:45pm
Long Acting Injectable vs. Oral Antipsychotics for
Schizophrenia: Meta-analytic Consideration of the
True Effect Size by the Study Designs
Taishiro Kishimoto, Keio University School of
Medicine, Department of Psychiatry
*of special interest to clinicians
46
Tuesday, June 17, 2014
1:15pm – 2:45pm
(continued)
*Long Acting Injectable Antipsychotics:
Perspectives on their Role in Schizophrenia
Treatment
Atlantic 3
1:45pm – 2:05pm
PROACTIVE: Exploring Longitudinal Course to
Understand Treatment Outcomes in LAI - oral
Comparisons
Nina R. Schooler, SUNY Downstate Medical Center
A Comparison of Long-acting Antipsychotic
Medications for Schizophrenia (ACLAIMS)
Joseph P. McEvoy, Georgia Regents University
2:25pm – 2:45pm
Discussion
2:45pm – 3:15pm
ASCP Business Meeting (ASCP Members Only)
Grand Ballroom
3:15pm – 3:30pm
Break
Ballroom Foyers
2:05pm – 2:25pm
Individual Research Reports
3:30pm – 4:30pm
Anxiety Disorder Presentations
Diplomat 1-2
Chair: Crystal Clark, Northwestern University Feinberg School of Medicine
Asher Center for the Study and Treatment of Depressive Disorders
3:30pm – 3:45pm
3:45pm – 4:00pm
A Rapidly Acting Intranasal Treatment for the
Symptoms of GAD
Michael R. Liebowitz, Pherin Pharmaceuticals
Comparative Effectiveness of Prolonged Exposure
(PE) and Sertraline(SER) in PTSD: Final Analyses
of The Impact of Choice and Treatment Preference
on Acute Outcome
Matig Mavissakalian, Case Western Reserve
University School of Medicine
*of special interest to clinicians
47
Tuesday, June 17, 2014
3:30pm – 4:30pm
(continued)
Anxiety Disorder Presentations
Diplomat 1-2
4:00pm – 4:15pm
Pharmacogenetic Study of Genetic Variations
across Remote Regulatory Regions of 14
Obsessive-Compulsive Disorder Candidate Genes
in Antidepressant Response
Gwyneth Zai, University of Toronto
Emotion Recognition Deficits in Treated and
Untreated Adults with ADHD
Anneka Tomlinson, University of Manchester
3:30pm – 4:30pm
Depression Presentations
Atlantic 1
4:15pm – 4:30pm
Chair: Bradley Gaynes, University of North Carolina School of Medicine
3:30pm – 3:45pm
3:45pm – 4:00pm
4:00pm – 4:15pm
4:15pm – 4:30pm
The Efficacy of Vortioxetine in Patients with Major
Depressive Disorder and High Levels of Anxiety
Symptoms: A Meta-analysis
David Baldwin, University of Southampton
Erythropoietin Induces Growth in Left
Hippocampus and Improves Verbal Memory in
Patients with Severe Affective Disorders
Kamilla Woznica Miskowiakm, Copenhagen University
Hospital
Epidural Cortical Stimulation of the Left DLPFC
Leads to Dose-dependent Enhancement of
Working Memory in Patients with MDD
Joan A. Camprodon, Massachusetts General Hospital,
Harvard Medical School
A Phase 1B, Randomized, Double-blind, Placebocontrolled, Multiple-dose Escalation Study
Evaluating the Effects of NSI-189 Phosphate, a
Neurogenic Compound, in Patients with Major
Depressive Disorder (MDD)
Marlene Freeman, Massachusetts General Hospital
= New Investigator
48
Tuesday, June 17, 2014
3:30pm – 4:30pm
Schizophrenia and Bipolar Disorder Presentations
Atlantic 2
Chair: Kristina Deligiannidis, University of Massachusetts Medical School/
UMass Memorial Medical Center
3:30pm – 3:45pm
3:45pm – 4:00pm
4:00pm – 4:15pm
4:15pm – 4:30pm
3:30pm – 4:30pm
Can Oxytocin Enhance Learning during Social
Cognitive Skills Training in Schizophrenia?
Michael C. Davis, VA Greater Los Angeles, University
of California Los Angeles
Hospitalization Rates in Patients Switched from
Oral Antipsychotics to Aripiprazole Once-monthly:
A Mirror Study
Timothy Peters-Strickland, Otsuka Pharmaceutical
Development &Commercialization, Inc.
Lithium Enhances Mitochondrial Complex I
Activity and Ameliorates DNA Methylation and
Hydroxymethylation Induced by Mitochondrial
Complex I Dysfunction
Ana Cristina Andreazza, University of Toronto
Varenicline for Smoking Cessation in Bipolar
Disorder: A Double-blind, Randomized, Placebocontrolled Trial
Roy K.N. Chengappa, University of Pittsburgh
Statistical Methods, Personality Disorders,
Substance Abuse, and Comorbidity Presentations
Atlantic 3
Chair: Katherine Burdick, Mount Sinai School of Medicine
3:30pm – 3:45pm
3:45pm – 4:00pm
Brain-derived Neurotrophic Factor Genotype and
Amygdala Habituation in Borderline Personality
Disorder
M. Mercedes Perez-Rodriguez, Mount Sinai School of
Medicine
Analysis and Missing Data Handling in Psychiatry
Trials with Inevitable, High, Differential and
Informative Discontinuations
Yangchun Du, Alkermes, Inc.
= New Investigator
49
Tuesday, June 17, 2014
3:30pm – 4:30pm
(continued)
Statistical Methods, Personality Disorders,
Substance Abuse, and Comorbidity Presentations
Atlantic 3
4:00pm – 4:15pm
Long-term Skeletal Effects of Risperidone and
SSRIs in Youths
Chadi Calarge, University of Iowa
Impulsivity and Substance Dependence: Metaanalysis and Possible Role in Treatment
Saddichha Sahoo, NIMHANS
4:30pm – 4:45pm
Break
Ballroom Foyers
4:15pm – 4:30pm
Workshops
4:45pm – 6:45pm
Cognitive Deficits in Depression: What are they?
Are they Independent Dimensions? Are they
Targets for Treatment?
Atlantic 1
Chair: Steven D. Targum, Clintara, LLC
Co-chair: Craig Nelson, UCSF
Discussant: Tiffany Farchione, US Food and Drug Administration
4:45pm – 4:50pm
Introduction
4:50pm – 5:10pm
Cognitive Impairment in Late Life Depression:
Type, Frequency, and Methods of Assessment
Scott Mackin, University of California, San Francisco
5:10pm – 5:30pm
5:30pm – 5:50pm
5:50pm – 6:10pm
Effects of Treatment on Cognition in Late Life
Depression
Craig Nelson, UCSF
Changes in Cognitive Symptoms before and
after Buspirone-melatonin Treatment for Major
Depressive Disorder
Steven D. Targum, Clintara, LLC
Changes in Cognitive Symptoms before and
after Vortioxetine Treatment in Major Depressive
Disorder
Maurizio Fava, Massachusetts General Hospital
50
Tuesday, June 17, 2014
4:45pm – 6:45pm
(continued)
6:10pm – 6:30pm
Cognitive Deficits in Depression: What are they?
Are they Independent Dimensions? Are they
Targets for Treatment?
Atlantic 1
Deficits in Mood Disorders: Impact on Functional
Outcomes and Treatment Strategies
Dan V. Iosifescu, Icahn School of Medicine at Mount
Sinai
6:30pm – 6:45pm
Discussion
4:45pm – 6:45pm
*Psychopharmacology of Residual Symptoms in
Mood Disorders and Schizophrenia
Atlantic 2
Chair: Jonathan Alpert, Massachusetts General Hospital, Harvard Medical
School
Discussant: Richard Shelton, University of Alabama at Birmingham
4:45pm – 4:50pm
Introduction
4:50pm – 5:15pm
Methodological and Design Issues in
Augmentation Trials
Thomas Laughren, MGH CTNI
5:15pm – 5:40pm
5:40pm – 6:05pm
6:05pm – 6:30pm
6:30pm – 6:45pm
New Approaches to the Treatment of Residual
Symptoms of Schizophrenia
Donald C. Goff, NYU Medical School
Residual Symptoms in Bipolar Disorder: The Role
of Polypharmacy
Joseph F. Goldberg, Icahn School of Medicine at
Mount Sinai
Studying the Efficacy of Adjunctive Therapies for
Depressive Disorders
Michael E. Thase, Perelman School of Medicine of the
University of Pennsylvania
Discussion
*of special interest to clinicians
51
Tuesday, June 17, 2014
4:45pm – 6:45pm
New Approaches to Funding Clinical Trials at NIMH
Atlantic 3
Chair: William Potter, National Institute of Mental Health
Discussant: David Kupfer, University of Pittsburgh School of Medicine
4:45pm – 5:00pm
Introduction
5:00pm – 5:20pm
First in Human and Early Stage Clinical Trials
of Novel Investigational Drugs or Devices for
Psychiatric Disorders
Meg Grabb, National Institute of Mental Health
5:20pm – 5:40pm
Exploratory Clinical Trials of Novel Interventions
for Mental Disorders
Jill Heemskerk, National Institute of Mental Health
Pilot Effectiveness Studies and Services Research
Grants
Chris Sarampote, National Institute of Mental Health
6:00pm – 6:45pm
Discussion
7:00pm – 8:00pm
ASCP Reception
South Palm Court
5:40pm – 6:00pm
52
Wednesday, June 18, 2014
AT-A-GLANCE
Wednesday, June 18, 2014
ASCP Steering Committee Meeting (Invitation only)
Room 308
7:30am – 8:30am
NIA Breakfast Roundtable (Invitation only)
Room 216
7:30am – 9:00am
Morning Break
Ballroom Foyers
8:15am – 9:45am
Keynote Session: New Approaches to Mental
Illness in the Era of the National Brain Initiative
Grand Ballroom
9:45am – 10:00am
Break
Ballroom Foyers
10:00am – 12:00pm
Plenary Session – NIH Institute Directors
Grand Ballroom
12:00pm – 2:00pm
Poster Session II with Lunch
Regency Ballroom
2:00pm – 3:30pm
Updates Session – The Latest on Treatment of
Mood, OCD-spectrum, and Binge Eating Disorders
Grand Ballroom
3:30pm – 3:45pm
Break
Ballroom Foyers
3:45pm – 5:45pmWorkshops
New Approaches
to Drug Studies for
Treating Social Deficits
in Autism Spectrum
Disorder
*Novel Mechanisms of
Action for the Treatment
of Depression and
Anxiety: Scientific
Updates
*Psychiatry and
Technology: A
Partnership in
Promoting Mental
Health
Location: Atlantic 1
Location: Atlantic 2
Location: Atlantic 3
*of special interest to clinicians
53
Wednesday
7:00am – 8:30am
Notes
54
Wednesday, June 18, 2014
FULL SCHEDULE
Wednesday, June 18, 2014
7:00am – 8:30am
ASCP Steering Committee Meeting (Invitation only)
Room 308
7:30am – 8:30am
NIA Breakfast Roundtable (Invitation only)
Room 216
7:30am – 9:00am
Morning Break
Ballroom Foyers
8:15am – 9:45am
Keynote Session: New Approaches to Mental
Illness in the Era of the National Brain Initiative
Grand Ballroom
Chair: Husseini K. Manji, M.D., FRCPC, Johnson & Johnson
Brain disorders are among mankind’s most devastating
illnesses. Worldwide, they place an enormous societal
burden on those affected. Indeed, in the United States
alone this burden of illness is rapidly approaching $1
trillion annually, a number that is only likely to escalate
in coming years with the aging population. In this
plenary session, Drs. Manji and Insel and Mr. Kennedy
will discuss interrelated facets in our search to better
understand the mechanisms underlying a wide range
of mental illnesses and to develop effective new
treatments for them.
Rapid advances in science and technology over the
past decade have provided us with an unprecedented
opportunity and the tools needed to unlock the secrets
of the brain. Dr. Insel will discuss the many significant
advances that have recently been made towards
understanding serious mental illnesses. Although public
and private resources devoted to research in this area
are diminishing, a host of cutting-edge approaches—
from genomics to data mining, proteomics to
biomarkers, pathway modeling to protein engineering,
neuroimaging to optogenetics—is nevertheless
revolutionizing the way we think about, study, and
approach the development of urgently needed novel
treatments for mental disorders, with extremely
promising results.
55
Wednesday, June 18, 2014
8:15am – 9:45am
(continued)
Keynote Session: New Approaches to Mental
Illness in the Era of the National Brain Initiative
Grand Ballroom
Dr. Manji will discuss the paradigm shift that must
accompany future research in this area. This
includes not only moving from a ‘diagnose and treat’
approach to a ‘predict and pre-empt’ model, but the
need to develop novel solutions that encompass
meaningful and measurable patient outcomes (for
instance, the ability to rapidly resume social and work
responsibilities).
Mr. Kennedy will discuss the many social issues that
can and must be addressed in any “whole-world”
view of mental illness, including parity for mental
health, ending the discrimination against patients, and
the travesty of homeless and imprisoned individuals
suffering from mental disorders.
The session will emphasize the speakers’ commitment
to a strong, united, cross-disciplinary approach towards
a key common goal: to work together across industry,
academia, government, and the private sector in a
concerted effort to improve the lives of the millions of
individuals affected by brain disorders. With such a
cooperative effort, real, tangible progress can be made.
8:15am – 8:25am
Introduction
Husseini K. Manji, M.D., FRCPC, Johnson & Johnson
8:25am – 8:55am
Thomas Insel, M.D., NIMH
8:55am – 9:25am
Patrick Kennedy, Former US Representative & Mental
Health Activist
9:25am – 9:45am
Discussion
9:45am – 10:00am
Break
Ballroom Foyers
56
Wednesday, June 18, 2014
10:00am – 12:00pm
Plenary Session – NIH Institute Directors
Grand Ballroom
Chair: David Kupfer, M.D., University of Pittsburgh School of Medicine
This year’s Institute Director’s session will bring
together directors from various NIH institutes who all
have a similar goal of searching for new approaches
in the research of mental disorders. Each director will
have ten minutes to discuss what activities are going
on within their institute regarding this goal. Thomas
Insel, NIMH Director, will begin the session discussing
transformation of clinical trials. Phil Skolnick will
discuss one of the more challenging issues that
NIDA faces is the epidemic of (both prescription and
non-prescription) opiate abuse. To put the problem
in perspective, it has been estimated that there are
3 million Americans currently abusing opioids; more
deaths result from opiate overdose than from firearms.
He will overview NIDA’s efforts to combat both opiate
abuse and overdose deaths. Kenneth Warren of NIAAA
will discuss the current framework for medications
development of alcohol use disorders. Josephine
Briggs will discuss NCCAM’s interest in encouraging
work on the neuroscience of the mind-body interface
and the mechanisms by which meditative practices
such as mindfulness, hypnosis, and meditative exercise
forms may impact on pain processing. Christopher
Austin will address NCATS’ unique role in the
biomedical ecosystem and the translational science
problems being prioritized by NCATS. He will also give
an overview of the Center’s programs and collaborative
opportunities. Finally, Richard Nakamura will discuss
the Center for Scientific Review’s steps to measure and
improve the performance of peer review. The session
will continue with an open dialogue Q&A session with
audience interaction.
Thomas Insel, M.D., NIMH
Phil Skolnick, Ph.D., NIDA
Kenneth Warren, Ph.D., NIAAA
Josephine Briggs, M.D., NCCAM
Christopher Austin, M.D., NCATS
Richard Nakamura, Ph.D., CSR
57
Wednesday, June 18, 2014
12:00pm – 2:00pm
Poster Session II with Lunch
Regency Ballroom
*See Pages 81 through 92 for poster listing.
2:00pm – 3:30pm
Updates Session – The Latest on Treatment of
Mood, OCD-spectrum, and Binge Eating Disorders
Grand Ballroom
Chair: Maurizio Fava, Massachusetts General Hospital
Recent advances in clinical neuroscience have led to
the development of novel treatments of mood, OCDspectrum, and binge eating disorders. The purpose
of this symposium is to provide an overview of the
latest developments in the pharmacological treatments
for these conditions. Dr. Papakostas will review new
approaches to the treatment of depression, as well as
to the identification of subpopulations of depressed
patients more likely to benefit from a given treatment.
Dr. Ketter will present an update on new therapeutic
developments in the treatment of bipolar disorder, such
as the approval by the FDA of asenapine, risperidone
long-acting injectable (LAI), ziprasidone, aripiprazole,
and lurasidone therapy for bipolar disorder. In addition,
Dr. Ketter will discuss the International Society for
Bipolar Disorders (ISBD) Antidepressant Use in Bipolar
Disorders Task Force controversial report from 2013.
Finally, Dr. Ketter will present data concerning some
novel pharmacological treatments for bipolar disorder. Dr.
McElroy will also provide an overview of the treatments
for hoarding disorder and binge eating disorder, new
discrete diagnostic entities in DSM-5. Psychological
treatments are effective for both conditions, but not all
patients respond and pharmacotherapy is emerging
as an important treatment option. Serotonin reuptake
inhibitors have been the most widely studied agents,
but both conditions respond modestly at best to these
compounds. Newer agents showing promise include
antiepileptics and psychostimulants. Available research
on the pharmacotherapy of HD and BED will be
reviewed, and future directions will be discussed.
2:00pm – 2:20pm
Hoarding Disorder and Binge Eating Disorder
Susan McElroy, University of Cincinnati College of
Medicine
58
Wednesday, June 18, 2014
2:00pm – 3:30pm
(continued)
Updates Session – The Latest on Treatment of
Mood, OCD-spectrum, and Binge Eating Disorders
Grand Ballroom
2:20pm – 2:40pm
Update on Bipolar Disorder Pharmacotherapy
Terence Ketter, Stanford University School of Medicine
2:40pm – 3:00pm
Update on Treatment of Major Depressive Disorder
George I. Papakostas, Massachusetts General
Hospital, Harvard Medical School
3:00pm – 3:30pm
Discussion
3:30pm – 3:45pm
Break
Ballroom Foyers
Workshops
3:45pm – 5:45pm
New Approaches to Drug Studies for Treating
Social Deficits in Autism Spectrum Disorder
Atlantic 1
Chair: Meg Grabb, National Institute of Mental Health
Co-chair: Ann Wagner, NIMH/NIH
Discussant: Alessandro Bertolino, F. Hoffmann-La Roche Ltd.
3:45pm – 3:50pm
Introduction
3:50pm – 4:10pm
Measuring Social Disability in Autism Spectrum
Disorder
Lawrence Scahill, Emory University
4:10pm – 4:30pm
4:30pm – 4:50pm
Honing in on Targets for Compound Selection in
ASD Trials: The NIMH FAST-ASD Network
James T. McCracken, UCLA Semel Institute
Incorporating Potential Functional Biomarkers in
Clinical Trials in ASD
Bryan H. King, Seattle Children’s Hospital and
University of Washington
Eye-tracking Measures of Social Disability as
Outcome Measures in School-age Children with ASD
Warren Jones, Marcus Autism Center
5:10pm – 5:45pm
Discussion
4:50pm – 5:10pm
59
Wednesday, June 18, 2014
3:45pm – 5:45pm
*Novel Mechanisms of Action for the Treatment of
Depression and Anxiety: Scientific Updates
Atlantic 2
Chair: Timothy Petersen, Clintara, LLC
Co-chair: Jaskaran Singh, Janssen Research and Development, LLC
Discussant: Randall D. Marshall, Alkermes
3:45pm – 3:50pm
Introduction
3:50pm – 4:10pm
A Review of Pre-clinical Data
Gerard Sanacora, Yale University
4:10pm – 4:30pm
Ketamine: Rationale, Empirical Evidence and New
Routes of Delivery
James W. Murrough, Icahn School of Medicine at
Mount Sinai
4:30pm – 4:50p
Treatment of Suicidality with Novel Mechanisms
Sanjay Mathew, Baylor College of Medicine
4:50pm – 5:10pm
The Role of Pherines for Rapid Relief of
Depressive and Anxiety Symptoms
Michael R. Liebowitz, Pherin Pharmaceuticals
5:10pm – 5:30pm
5:30pm – 5:45pm
Novel Developments in Non-invasive
Neurostimulation for the Treatment of Mood
Disorders
Dan V. Iosifescu, Icahn School of Medicine at Mount
Sinai
Discussion
*of special interest to clinicians
60
Wednesday, June 18, 2014
3:45pm – 5:45pm
*Psychiatry and Technology: A Partnership in
Promoting Mental Health
Atlantic 3
Chair: Holly A. Swartz, University of Pittsburgh School of Medicine
Discussant: Ellen Frank, University of Pittsburgh School of Medicine
3:45pm – 3:50pm
Introduction
3:50pm – 4:10pm
MoodSwings 2.0 for Bipolar Disorder:
www.moodswings.net.au
Victoria E. Cosgrove, Stanford University School of
Medicine
4:10pm – 4:30pm
4:30pm – 4:50pm
MoodRhythm: Pilot Testing a Smartphone App for
Monitoring Mood and Daily Routines
Mark Matthews, Cornell University
Using Smartphones to Enhance Skill Acquisition
and Utilization in CBT for Child Anxiety
Jennifer Silk, University of Pittsburgh
Computerized Adaptive Testing (CAT) and the
Future of Psychiatric Measurement
Robert Gibbons, University of Chicago
5:10pm – 5:45pm
Discussion
4:50pm – 5:10pm
*of special interest to clinicians
61
Notes
62
Thursday, June 19, 2014
AT-A-GLANCE
Thursday, June 19, 2014
7:30am – 9:00am
Morning Break
Ballroom Foyers
8:30am – 10:00am
Panel Sessions
The NIMHFunded RAPID
Network Studies
Leveraging the
Internet and
Social Media
to Improve
Pathways to Care
and Shorten DUP
in Schizophrenia
Practical Trials
in Psychiatry:
The Need, The
Opportunities
Location:
Diplomat 1-2
Location:
Atlantic 1
Location:
Atlantic 2
Location:
Atlantic 3
10:00am – 10:15am
Break
Ballroom Foyers
10:15am – 11:45am
Plenary: Regulatory Wrap-up Session
Grand Ballroom
12:00pm
Meeting Adjourns
63
Thursday
Clinical Trials
in Early Stage
Alzheimer’s
Disease: Current
Methodological
and Regulatory
Considerations
Notes
64
Thursday, June 19, 2014
FULL SCHEDULE
Thursday, June 19, 2014
7:30am – 9:00am
Morning Break
Ballroom Foyers
Panel Sessions
8:30am – 10:00am
Clinical Trials in Early Stage Alzheimer’s
Disease: Current Methodological and Regulatory
Considerations
Diplomat 1-2
Chair & Discussant: Kathleen Welsh-Bohmer, Joseph and Kathleen Bryan
Alzheimer’s Disease Research Center
8:30am – 8:40am
Introduction
8:40am – 9:00am
What Are We Trying to Measure in Preclinical and
Prodromal Alzheimer’s Disease?
Lon S. Schneider, Keck School of Medicine of USC
What are the Optimal Cognitive Outcome
Measures for Trials in Preclinical Alzheimer’s
Disease?
Keith Wesnes, Bracket Global
9:20am – 9:40am
Drug Development Cognition Challenges
Marc Cantillon, Kyowa Hakko Kirin Pharma, Inc.
9:40am – 10:00am
Discussion
9:00am – 9:20am
65
Thursday, June 19, 2014
8:30am – 10:00am
The NIMH-Funded RAPID Network Studies
Atlantic 1
Chair: Maurizio Fava, Massachusetts General Hospital
Co-chair: Mi Hillefors, NIMH
Discussant: Carlos A. Zarate, NIMH
8:30am – 8:40am
Introduction
8:40am – 9:00am
A POC of Low-field Magnetic Stimulation:
Methodological Issues and Innovations in the
Implementation of a Novel Device Study in MDD
Maurizio Fava, Massachusetts General Hospital
9:00am – 9:20am
Potential Rapid Antidepressant Augmentation with
a Selective Kappa Antagonist
Sitra Tauscher-Wisniewski, Lilly Research Labs
A Dose-finding Study of I.V. Ketamine in
Treatment-resistant Depression
Gerard Sanacora, Yale University School of Medicine
9:40am – 10:00am
Discussion
8:30am – 10:00am
Leveraging the Internet and Social Media to
Improve Pathways to Care and Shorten DUP in
Schizophrenia
Atlantic 2
9:20am – 9:40am
Chair: John M. Kane, The Zucker Hillside Hospital
Discussant: Donald C. Goff, NYU Medical School
8:30am – 8:40am
Introduction
8:40am – 8:55am
Duration of Untreated Psychosis and it’s
Correlates in Patients with Schizophreniaspectrum Disorders: Results from a Large Metaanalysis of First Episode Studies
Christoph Correll, The Zucker Hillside Hospital
8:55am – 9:10am
Understanding Pathways to Care in Early-course
Psychotic Disorders
Michael T. Compton, Hofstra North Shore-LIJ School
of Medicine at Hofstra University
66
Thursday, June 19, 2014
8:30am – 10:00am
(continued)
Leveraging the Internet and Social Media to
Improve Pathways to Care and Shorten DUP in
Schizophrenia
Atlantic 2
9:10am – 9:25am
Early Detection of Psychosis through Self-report
Screening
Rachel Loewy, University of California
Reducing DUP in the Age of Social Media and the
Internet
John M. Kane, The Zucker Hillside Hospital
9:40am – 10:00am
Discussion
8:30am – 10:00am
Practical Trials in Psychiatry: The Need, The
Opportunities
Atlantic 3
9:25am – 9:40am
Chair & Discussant: Benedetto Vitiello, NIMH
Co-chair: Nina R. Schooler, SUNY Downstate Medical Center
8:30am – 8:40am
Introduction
8:40am – 8:55am
Practical, Pragmatic, and Possible
Psychopharmacology Clinical Trials: Lessons
Learned from the AHRQ Bipolar CHOICE study
Andrew Nierenberg, Massachusetts General Hospital
8:55am – 9:10am
9:10am – 9:25am
Expanding the Place of Practice-based Clinical
Trials on the Explanatory-pragmatic Spectrum
Greg Simon, Group Health Research Institute
A Regulatory Perspective on Practical Clinical
Trials
Thomas Laughren, MGH CTNI
9:25am – 9:40am
PCORI and Practical Trials in Mental Health
Grayson Norquist, The University of Mississippi
Medical Center
9:40am – 10:00am
Discussion
67
Thursday, June 19, 2014
10:00am – 10:15am
Break
Ballroom Foyers
10:15am – 11:45am
Plenary: Regulatory Wrap-up Session
Grand Ballroom
Chair: Ni A. Khin, M.D., U.S. Food and Drug Administration
Phillip Kronstein, M.D., Food and Drug Administration
Celia Winchell, M.D., Food and Drug Administration
Silvana Borges, M.D., Food and Drug Administration
12:00pm
Meeting Adjourns
68
Posters
Tuesday, June 17, 2014
Poster Session 1
A Double-blind, Randomized, Placebo-controlled, Parallel Group,
Dose Frequency Study of Intravenous Ketamine in Patients with
Treatment-Resistant Depression
Jaskaran Singh, Janssen Research and Development, LLC
P-2
A Pilot Study of a Novel Monoamine Triple Reuptake Inhibitor
EB-1020 SR in the Treatment of ADHD in Adults
Timothy Wilens, Massachusetts General Hospital
Andrew J. Cutler, Ann Childress, Randall D. Marshall, Mark
Bradshaw, Frank Bymaster, Anthony McKinney, Stephen W. Hurt,
Catherine O’Brien, Timothy Hsu
P-3
AZD8529, a Positive Allosteric Modulator of the mGiuR2
Receptor for the Treatment of Schizophrenia
Alan Cross, AstraZeneca Neuroscience Innovative Medicines Unit
P-4
Efficacy and Safety of a Novel mGlu2 Receptor Positive Allosteric
Modulator as an Adjunctive Treatment to an SSRl/SNRI in the
Treatment of Anxious Depression
Justine Kent, Janssen
Ella Daly, Ceusters Marc, Iva Kezic, Rosanne Lane, Lim Pilar, De
Smedt Heidi, Mazzucco Christine, Peter DeBoer, Luc Van Nueten,
Wayne Drevets
P-5
Lupron in Combination with an Acetylcholinesterase Inhibitor
Halts Cognitive Decline in Women with Alzheimer ‘s Disease over
a 48 Week Period
Richard Bowen, OTB Research
Craig Atwood
P-6
Results of a Phase 28 Clinical Trial of TC-5619, a Selective
Alpha 7 Neuronal Nicotinic Receptor (NNR) Agonist in the
Adjunctive Treatment of Negative Symptoms and Cognitive
Dysfunction in Schizophrenia
David Hosford, Targacept, Inc.
Chris Dvergsten, Jessica Beaver, Anthony Segreti, Steven
Toler, Gaston Farr, Melissa Joseph, John Jett, Patrick Lippiello,
Merouane Bencherif
P-7
A Rapidly Acting Intranasal Treatment for the Symptoms of GAD
Michael Liebowitz, Pherin Pharmaceuticals
Louis Monti, Rita Hanover, Bernard Grosser
P-8
Metadoxine Extended Release (MDX): A Novel Drug Candidate for
the Treatment of ADHD & Other Cognitive Disorders
Jonathan Rubin, Alcobra Pharma
Yaron Daniely, Lenard Adler
*P-# References a Pharmaceutical Pipeline Presentation.
69
Posters
P-1
Posters
1
Memantine in the Treatment of Executive Function Deficits in
Adults with ADHD: A Pilot Randomized Double Blind Controlled
Clinical Trial
Joseph Biederman, Massachusetts General Hospital
Ronna Fried, Laura M. Tarko, Craig Surman, Stephen V. Faraone,
Thomas Spencer
2
Effects of Lisdexamfetamine Dimesylate on Brain Reward
Circuitry in Adults with ADHD
Stephanie Duhoux, Icahn School of Medicine at Mount Sinai
Kurt Schulz, Beth Krone, Anne-Claude V. Bédard, Juan D. Pedraza,
Lenard Adler, Stuart F. White, James Blair, Jeffrey Newcorn
3
The Methylphenidate-atomoxetine Crossover Study in ADHD
Youth: Measuring and Comparing Response
Mark Stein, The University of Washington
Tom Hildebrandt, Jeffrey Newcorn
4
The Role of Aldosterone and Cortisol in Alcohol Use Disorders in
a Baclofen Treatment Study
Elie G. Aoun, Brown University, Butler Hospital
Carolina Haass-Koffler, Robert Swift, Giovanni Addolorato, George
Kenna, Lorenzo Leggio
5
Addiction Severity Index Family Composite Scale More Reliable
Than Combined Family/Social Composite
Wayne H. Denton, Florida State University
Jacob B. Priest, Sarah B. Woods
6
Periodic Placebo Effect in an Addiction Therapy Trial
Bernard L. Silverman, Alkermes, Inc.
Jacqueline Zummo, Asli Memisoglu, David Gastfriend, Walter Ling,
Evgeny Krupitsky
7
Adrenergic Receptor Modulation for the Treatment and Prevention
of Post-traumatic Stress Disorder and Co-morbid Disorders
Chaya G. Bhuvaneswaran, University of Massachusetts-Worcester
8
An Epigenome-wide Assessment of Atypical Antipsychotic Side
Effects in Bipolar Disorder
Kyle J. Burghardt, University of Michigan College of Pharmacy
Vicki L. Ellingrod
= New Investigator
70
Posters
9
Biomarkers of Cardiometabolic Risk in Antipsychotic Treated
Youth
Ginger E. Nicol, Washington University School of Medicine
Michael D. Yingling, Julia A. Schweiger, John Newcomer
10
Plasma Polyunsaturated Fatty Acid Markers Differ in Symptomatic
Bipolar Disorder
Erika Saunders, Penn State College of Medicine, Penn State
University
Kaizong Ma, Eric Schaefer, Alan Gelenberg, Stanley Rapoport
11
Reliable Change Index and Clinical Significance in Clinical Trials
Using the Positive and Negative Syndrome Scale (PANSS)
Mark Opler, ProPhase LLC, New York University School of Medicine
Anzalee Khan, Linda Gao, Brian Rothman, Luka Lucic
12
Prenatal Stress Evokes Long-term Changes in Brain Glucose
Metabolism
Boguslawa Budziszewska, Institute of Pharmacology, Polish Academy
of Sciences
Anna Kurek, Jan Detka, Agnieszka Basta-Kaim, Monika Leśkiewicz,
Marta Kubera
13
Efficacy and Safety of Treatment with Lurasidone Adjunctive
with Lithium or Valproate in Bipolar I Depression: Results of Two
6-week Studies
Joseph R. Calabrese, Case Western Reserve School of Medicine
Trisha Suppes, Kaushik Sarma, Robert Silva, Hans Kroger, Josephine
Cucchiaro, Andrei Pikalov, Antony Loebel
14
MoodSwings 2.0 (www.moodswings.net.au): An Online
Intervention for Bipolar Disorder
Victoria E. Cosgrove, Stanford University School of Medicine
Trisha Suppes, Sue Lauder, Emma Gliddon, Karishma Raju, Seetal
Dodd, E. Grace Fischer, Michael Berk
15
Clinically Relevant Change Using CGI-BP in Patients with Acute
Depressive Episodes of Bipolar I or II Disorder in Quetiapine XR
Study
Catherine Datto, AstraZeneca
Jason Wright, Scott LaPorte, Michelle Shay
71
Posters
16
Number Needed to Treat for Discontinuation Due to Adverse
Events, Somnolence, ≥ 7% Weight Gain, Extrapyramidal Side
Effects, Response, and Remission of Atypical Antipsychotics in
Acute Bipolar Depression
Keming Gao, Case Western Reserve University
17
Lurasidone in Bipolar I Depression: A 24 Week, Open-label
Extension Study
Terence Ketter, Stanford University School of Medicine
Kaushik Sarma, Robert Silva, Hans Kroger, Josephine Cucchiaro,
Antony Loebel
18
Sleep Patterns across the Bipolar Spectrum: Similarities and
Differences between Mood States and Across Diagnostic
Subtypes
Jessica C. Levenson, University of Pittsburgh
Holly A. Swartz, Ellen Frank, David J. Kupfer
19
Global Improvement in Bipolar Mania Patients Treated with
Cariprazine
Robert E. Litman, CBH Health, LLC
Kaifeng Lu, Krisztián Nagy, István Laszlovszky, Suresh Durgam
20
Psychopharmacology Algorithm for Acute Mania
David Osser, Harvard Medical School
Othman Mohammad
21
The Psychopharmacology Algorithm Project at the Harvard South
Shore Program: 2014 Update on Bipolar Depression
Dana Wang, Harvard Medical School, VA Boston Healthcare System
Arash Ansari, David Osser
22
Correlation between Different Levels of Placebo Response Rate
and Clinical Trial Outcome in Bipolar Depression
George I. Papakostas, Massachusetts General Hospital, Harvard
Medical School
Nadia Iovieno, Rosemary Walker
23
Resilience in High-risk Infants and Toddlers of Mothers with
Bipolar Disorder: A Longitudinal Investigation
Diana I. Simeonova, Emory University School of Medicine
Theresa Nguyen, Kerry Ressler, W. Edward Craighead
= New Investigator
72
Posters
24
A Dimensional Assessment of Anxiety and Tic Severity in
Tourette’s Disorder
Barbara Coffey, Icahn School of Medicine at Mount Sinai, Nathan S.
Kline Institute for Psychiatric Research
Vilma Gabbay
25
Computerized Adaptive Diagnosis and Testing in Psychiatric
Outpatients Seeking Care at a Large, Free-standing Psychiatric
Hospital
Eric D. Achtyes, Michigan State University College of Human Medicine
Scott Halstead, LeAnn D. Smart, Robert D. Gibbons
26
A Dimensional Rating System for Psychiatric Disorders in
Psychiatric Outpatients
Mark Zimmerman, Rhode Island Hospital
27
A Clinically Useful Self-report Measure of the DSM-5 Anxious
Specifier of Major Depressive Disorder
Mark Zimmerman, Rhode Island Hospital
28
Reduction of Placebo Response in Depression Trials via
Independent Remote (SAFER) Patient Interviews
Martina J. Flynn, Massachusetts General Hospital Clinical Trials
Network and Institute
Marlene Freeman, Maurizio Fava, David Mischoulon, James Pooley,
Daniel Burch, Heather Bryson
29
A Comparison of Cross-cultural Regional Norms for the MATRICS
Consensus Cognitive Battery (MCCB)
Richard S. E. Keefe, NeuroCog Trials, Duke University
Ioan Stroescu, Vicki G. Davis, Alexandra S. Atkins
30
Magnitude of Change with Antidepressants and Placebo in
Antidepressant Clinical Trials Using Structured, Taped and
Appraised Rater Interviews Compared to Traditional Semistructured Interviews
Arif Khan, Northwest Clinical Research Center
James Faucett, Walter Brown
31
The Impact of Implementing a National Research Subject
Database to Prevent Dual Enrollment in Early and Late Phase
Central Nervous System Trials
Kerri Weingard, Accumed Research Associates & Verified Clinical Trials
Mitchell Efros
= New Investigator
73
Posters
32
Early Life Stress as a Risk Factor for Substance Use Disorders:
Clinical and Neurobiological Substrates
Sajoy Purathumuriyil Varghese, Rosalind Franklin University of
Medicine and Science
33
Panic Disorder: Theoretical Overlap with Narcolepsy
Thomas W. Uhde, MUSC
Bernadette M. Cortese, Priyattam Shiromani, Orlena Merritt-Davis,
Yury Yaroslavsky, Ravi Singareddy, Kimberly R. Leslie, Martha
Strachan, Jennifer Runion, David Bachman, Richard K. Bogan
34
A Five Year Observational Study of Patients with Treatment
Resistant Depression Treated with VNS Therapy® or Treatment
as Usual: Comparative Response/Remission Rates, Duration of
Response, and Quality of Life
Scott T. Aaronson, Sheppard Pratt Health System
Mark T. Bunker, Peter Sears, Francis Ruvuna
35
Prenatal Stress Influences the Proper Functioning of the Primary
Microglial Cells and Leads to Behavioral Changes in Adult
Offspring - A Link to Depression
Agnieszka Basta-Kaim, Institute of Pharmacology, Polish Academy of
Sciences
Joanna Slusarczyk, Bogusława Budziszewska, Monika Leśkiewicz,
Marta Kubera
36
The Efficacy of Vilazodone in Achieving Remission in Patients
with Major Depressive Disorder: Post Hoc Analyses of a Phase IV
Trial
Leslie Citrome, New York Medical College
Carl Gommoll, Xiongwen Tang, Rene Nunez, Maju Mathews
37
Clinical Relevance of Levomilnacipran ER Treatment in Patients
with Major Depressive Disorder: Improvements in Functional
Impairment Categories
Andrew J. Cutler, Florida Clinical Research Center, LLC
Carl Gommoll, Changzheng Chen, William M. Greenberg, Adam Ruth
38
Levomilnacipran Inhibits both Norepinephrine and Serotonin
Reuptake across the Clinical Dose Range
Tobie Escher, Forest Research Institute
Joann O’Connor, Laishun Chen, Carl Gommoll, Stephen Zukin
74
Posters
39
Increased ACC and Striatal Total Choline Levels in Adolescent
Depression
Vilma Gabbay, Icahn School of Medicine at Mount Sinai; Nathan S.
Kline Institute for Psychiatric Research
Ana I. Vallejo, Amy R. Johnson
40
Cognitive Domains Impacted by Vortioxetine Treatment of
Patients with Major Depressive Disorder (MDD)
John E. Harrison, Metis Cognition Ltd.
Søren N. Lophaven, Christina Kurre Olsen
41
A Head-to-head, Randomized, Comparison Study of Vortioxetine
vs. Escitalopram in Patients Well Treated for MDD and
Experiencing Treatment-emergent Sexual Dysfunction
Paula L. Jacobsen, Takeda Development Center Americas
Atul R. Mahableshwarkar, Yinzhong Chen, Lambros Chrones, Anita
Clayton
42
The Role of Pro-inlammatory Cytokines in Modulation of Activity
of Serotoninergic System in Women with Postpartum Depressive
Symptoms and in Animal Models of Depression
Marta Kubera, Institute of Pharmacology, Polish Academy of Sciences
Katarzyna Curzytek, Weronika Duda, Joanna Slusarczyk, Monika
Leskiewicz, Krystyna Golembiowska, Magdalena Regulska, Agnieszka
Basta-Kaim, Bogusława Budziszewska, Wladyslaw Lason, Michael
Maes
43
Anti-anhedonic Effect of Ketamine and its Neural Correlates in
Major Depressive Disorder
Níall Lally, National Institutes of Health
Allison C. Nugent, David Luckenbaugh, Carlos Zarate
44
ALKS 5461, a Novel Opioid Modulator as Adjunctive Treatment for
Depression: Addressing Abuse Potential, Safety and Efficacy
Randall D. Marshall, Alkermes, Inc.
Ryan Turncliff, J. Alexander Bodkin, Lauren E. DiPetrillo, Richard
Leigh-Pemberton, Michael E. Thase, Madhukar Trivedi, Asli
Memisoglu, Maurizio Fava
45
Effects of Vilazodone on Sexual Dysfunction in Major Depressive
Disorder: A Randomized, Double-blind Trial with Placebo and
Active Controls
Maju Mathews, Forest Research Institute
Carl Gommoll, Dalei Chen, Rene Nunez
75
Posters
46
A 8-week Randomized, Double-blind Trial Comparing Efficacy,
Safety and Tolerability of Three Vilazodone Dose Initiation
Strategies Following Switch from SSRIs or SNRIs in Major
Depressive Disorder
Robert Millet, Duke University
Shilpa Rele, Sungman Kim, Jong-Woo Paik, Seonghwan Kim, Varun
Kasula, Prakash Masand, Ashwin Patkar
47
Adjunctive Lanicemine (AZD6765) in Patients with Major
Depressive Disorder and a History of Inadequate Response to
Antidepressants: Post-hoc Analyses of a Randomized, Placebo
Controlled Study (PURSUIT)
Sanjeev Pathak, AstraZeneca
Hong-Lin Su, Joel Posener, Khanh Bui, Michael Quirk, Tim Piser,
Sanjay Mathew, Gerard Sanacora
48
The Rosenberg Hassman Mood Scale - An Update on the
Development of This Depression Rating Scale with Feedback
from 50 Patients
Leon I. Rosenberg, Center for Emotional Fitness
Keith Wesnes, Sanju George, Howard Hassman, Mary Gelovich
49
Efficacy of Vortioxetine vs. Placebo in Adults with Major
Depressive Disorder (MDD): Meta-analyses of MADRS Single
Items from 9 Short-term Studies
Michael E. Thase, Perelman School of Medicine of the University of
Pennyslvania
Atul R. Mahableshwarkar, Henrik Loft, Marianne Dragheim
50
mTOR Signaling Correlates with Treatment Response to Ketamine
in a Preclinical Model of Treatment Resistant Depression
Susannah J. Tye, Mayo Clinic
Adam Walker, Blair Price, Chunling Hu, Shari Sutor, Mark A. Frye
51
A Novel Trial Design to Assess Rapid and Sustained
Antidepressant Effects of an Oral NR2B Specific NMDA Receptor
Antagonist, CERC-301
James Vornov, Cerecor, Inc.
Maurizio Fava, Michael Detke, Chao Wang, Larry Ereshefsky, Richard
C. Shelton, Michael E. Thase, Madhukar Trivedi
76
Posters
52
An International Study of the GRID-HAMD: Has It Fulfilled Its
Promise?
Janet Williams, MedAvante, Inc.
Matej Ondrus, Melanie Rishton, Jennie K. Persson, Marlene Popescu,
Risto Valjakka
53
Validation of the Yale-Brown Obsessive Compulsive Scale
Modified for Binge Eating to Support Use in Clinical Trials as a
Measure of Treatment Benefit
Linda Deal, Shire Development LLC
Robert Wirth, Barry Herman, Maria Gasior, Susan McElroy
54
Acquired Binge-eating Behaviour Produces Alterations in
Dopaminergic Neurochemistry in the Brains of Rats
Peter Hutson, Shire
Jane Gosden, Mike Prow, David J. Heal, Sharon Cheetham
55
Definitive Verification and Monitoring of Oral Medication
Adherence Using Breath Analysis
Donn M. Dennis, Xhale SMART, Inc.
Eileen Loskie
56
Predictors of Pharmacological Treatment Response in Grooming
Disorders
Brian L. Odlaug, University of Copenhagen
Jon E. Grant, Eric Leppink, Katherine L. Derbyshire
57
Web-based Curriculums for Teaching Psychopharmacology:
Revision of the Resident and the Medical Student Curriculums
Ira Glick, Stanford University School of Medicine
58
The Effects of Social Support on Suicidality in an Adult Inpatient
Psychiatric Population as Assessed by the C-SSRS and S-STS
Ahmad Hameed, Penn State College of Medicine
Amanda M. White, Michael Mitchell, Eric A. Youngstrom, Roger E.
Meyer, Alan J. Gelenberg
59
Deconstructing Drug Company Promotion: Pursuing Truth: Slides
for a 1 Hour Lecture in a Psychopharmacology Course
Jeffrey Mattes, Psychopharmacology Research Association of
Princeton
77
Posters
60
Metabotropic Glutamate Receptor 7 (GRM7) Pharmacogenetics in
First Episode Psychosis
James M. Stevenson, University of Illinois College of Pharmacy
James L. Reilly, Margret S. H. Harris, Konasale M. Prasad, Judith
A. Badner, Vishwajit Nimgaonkar, Matcheri S. Keshavan, John A.
Sweeney, Jeffrey R. Bishop
61
Medical Informatics in Psychiatric Practice: Current Status and
Unmet Needs
Farifteh Duffy, American Psychiatric Association/American Psychiatric
Foundation
Laura Fochtmann, Robert M. Plovnick, Diana E. Clarke, Eve K.
Mościcki, William Narrow
62
All-cause Discontinuation and Safety of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of
Two Double-blind, Randomized, Controlled Trials
Ross A. Baker, Otsuka Pharmaceutical Development &
Commercialization, Inc.
W. Wolfgang Fleischhacker, Raymond Sanchez, Lan-Feng Tsai,
Timothy Peters-Strickland, Anna Eramo, John Kane
63
Subject Recruitment Strategies: A New Cross-functional Team
Approach
Kim Cheshire-Kinney, Janssen Research & Development, LLC
Stephen Rodriguez, James O’Neill, Lucy Mahalchick, Allen Wu
64
Accelerated Aging in Severe Mental Illness Using Levels of
Advanced Glycated Endproducts as Indicator. Research Findings
and Clinical Consequences
Dan Cohen, Mental Health Organization North-Holland North
Annet Nugter, Andries Smit
65
A Double-blind, Placebo-controlled, Randomized Withdrawal
Study of Lurasidone for the Maintenance of Efficacy in Patients
with Schizophrenia
Josephine Cucchiaro, Sunovion Pharmaceuticals, Inc.
Rajiv Tandon, Antony Loebel, Debra Phillips, David Hernandez,
Yongcai Mao, Andrei Pikalov
66
Categorical Improvements in Disease Severity in Schizophrenia
Patients Treated with Cariprazine
Suresh Durgam, Forest Research Institute
Stephen Zukin, Kaifeng Lu, Marc Debelle, István Laszlovszky, Stephen
Volk
78
Posters
67
Efficacy and Safety of Aripiprazole Once-monthly in Obese and
Non-obese Patients with Schizophrenia: A Post Hoc Analysis
Anna Eramo, H. Lundbeck A/S
Marc De Hert, Wally Landsberg, Lan-Feng Tsai, Ross A. Baker
68
The Effects of Caloric Vestibular Stimulation on Illness Awareness
in Schizophrenia: A Pilot, Proof of Concept Study
Philip Gerretsen, Centre for Addiction and Mental Health
David D. Pothier
69
Comparative Outcomes after Switching from Risperidone Longacting Injectable to Paliperidone Long-acting Injectable or Oral
Antipsychotics
David Hough, Janssen Research & Development
Erica Voss, Larry Alphs, Patrick Ryan, Paul Stang
70
Exploring Neuropathological Deficits and New Drug Targets for
Major Psychiatric Disorders Using the Stanley Neuropathology
Consortium Datasets and RNA-Seq Data
Sanghyeon Kim, Stanley Medical Research Institute
71
Clozapine May Exert Its Superior Efficacy on Schizophrenia
through Its Serotonin 5HT2C Receptor Inverse-agonism
Sanghyeon Kim, Stanley Medical Research Institute
72
An Open-label Extension Study of Lurasidone Safety and Efficacy
in Patients with Schizophrenia Previously Randomized to
Lurasidone or Risperidone
Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
Gregory Mattingly, Michael Tocco, Debra Phillips, Jane Xu, Antony
Loebel
73
Correlates or Social Cognition and Neurocognition to Functional
Outcomes
Brian Rothman, ProPhase, LLC
Jean-Pierre Lindenmayer, Anzalee Khan, Mark Opler, Linda Gao
74
A Randomized Blind Parallel Intramuscular Haloperidol-controlled
Multicenter Clinical Trial to Evaluate the Efficacy and Safety of
Intramuscular Levosulpiride in the Treatment of Chinese Patients
with Agitation of Schizophrenia
Yifeng Shen, Shanghai Mental Health Center
Huafang Li
= New Investigator
79
Posters
75
Varenicline Effects on Smoking, Cognition, and Psychiatric
Symptoms in Schizophrenia: Results of a Double-blind Placebo
Controlled Study
Robert C. Smith, NYU School of Medicine and Nathan Kline Institute
for Psychiatric Research
76
Paliperidone Research in Demonstrating Effectiveness (PRIDE):
Managing Schizophrenia Patients with a History of Incarceration
H. Lynn Starr, Janssen Scientific Affairs, LLC
Larry Alphs, Lian Mao, Stephen Rodriguez
77
A Randomized, Placebo-controlled Repeat-dose Thorough QT
Study of Inhaled Loxapine in Healthy Volunteers
Paul P. Yeung, Teva Pharmaceuticals
James V. Cassella, Daniel A. Spyker
78
Lamotrigine: Are We Dosing it Optimally in Pregnant Women with
Bipolar Disorder?
Crystal T. Clark, Northwestern University Feinberg School of Medicine
79
Sexual Symptoms Associated with Leuprolide Acetate Therapy in
Infertility Patients Treated for Endometriosis
Julia “Jill” K. Warnock, University of Oklahoma-HSC- Tulsa
J. Clark Bundren
80
Posters
Wednesday, June 18, 2014
Poster Session 2
1
A Novel Computer-prompted Tandem Rating Assessment for
Adult ADHD Clinical Trials
Joan Busner, Penn State College of Medicine and Bracket
Andrew J. Cutler, Gary S. Sachs, Dan DeBonis, Timothy Hsu,
Catherine O’Brien, Timothy Wilens
2
Emotional Dysregulation as an Adult ADHD Subtype
Frederick W. Reimherr, Psychiatric & Behavioral Solutions, University
of Utah
Tammy A. Steans, Kathleen Reimherr, Phillip D. Gale, Thomas Gift,
Paul H. Wender, Barrie K. Marchant
3
Emotion Recognition Deficits in Treated and Untreated Adult
ADHD Patients
Anneka Tomlinson, University of Manchester
Robert Baskind, Joe Johnson, Kay Marshall, Joanna C. Neill
4
Attenuation of Ethanol Withdrawal by Ceftriaxone-induced
Upregulation of Glutamate Transporter EAAT2
Ulas M. Camsari, Mayo Clinic
Osama Abulseoud
5
A Double-blind, Placebo-controlled Trial Assessing the Efficacy of
Varenicline Tartrate for Alcohol Dependence
Raye Z. Litten, NIAAA
Joanne B. Fertig, Daniel E. Falk, Megan L. Ryan
6
Progesterone Treatment for Postpartum Cocaine Users
Kimberly Yonkers, Yale School of Medicine
Mehmet Sofuoglu, Kathleen Carroll
7
Desvenlafaxine ER vs. Placebo in Social Anxiety Disorder
Michael R. Liebowitz, Pherin Pharmaceuticals
Ester Salman, Ann E. Johnson, Rita Hanover
8
The Predictive Value of Gene Variants Used to Guide
Antidepressant Selection
Kevin M. Furmaga, Pine Rest CMHS and Michigan State University
College of Human Medicine (Psychiatry)
Andrew C. Rose, LeAnn D. Smart, Alan T. Davis, Eric D. Achtyes
81
Posters
9
Determining Pharmacological Selectivity of the Kappa Opioid
Receptor Antagonist LY2456302 Using Translational Rat to Human
Pupillometry Studies
Linda Rorick-Kehn, Lilly Research Laboratories, Eli Lilly and Co
10
A Naturalistic Study of the Clinical Utility of Pharmacogenetic
Testing in Psychiatric Patients
Rachel Scott, Genomind
Herbert Harris, Kathryn Gardner, Jay Lombard, Francis X. Brennan
11
How Cardinal are Cardinal Symptoms in Pediatric Bipolar
Disorder? A Familial Risk Analysis
Joseph Biederman, Massachusetts General Hospital
Stephen V. Faraone, Laura M. Tarko, Mariely Hernandez, Janet
Wozniak
12
High EPA Omega-3 Fatty Acids and Inositol as Monotherapy and
in Combination in the Treatment of Pediatric Bipolar Disorder: A
Pilot Double-blind Randomized Clinical Trial
Joseph Biederman, Massachusetts General Hospital
Stephen V. Faraone, Laura M. Tarko, Mariely Hernandez, Janet
Wozniak
13
Identifying Patients Meeting the DSM-5 Criteria for Bipolar
Disorder Episodes with Mixed Features in Bipolar Disorder
Studies with Quetiapine XR
Catherine Datto, AstraZeneca
Jason Wright, Scott LaPorte, Michelle Shay
14
Lurasidone Monotherapy for Bipolar Depression: Influence of
Baseline Thyroid Function on Treatment Response
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai
Andrei Pikalov, Kei Watabe, Antony Loebel
15
Screening and Validation of Novel Kinase Signaling Pathways for
Neuronal Excitability
Wei-Chun Hsu, University of Texas Medical Branch at Galveston
Miroslav Nenov, Alexander Shavkunov, Neli Panova-Elektronova,
Fernanda Laezza
16
Mediators of Effects of Lurasidone on Functioning and Quality
of Life: Results from a Randomized, Double-blind, Placebocontrolled Trial in Patients with Bipolar I Depression
Terence Ketter, Stanford University School of Medicine
Cynthia Siu, Krithika Rajagopalan, Andrei Pikalov, Antony Loebel
82
Posters
17
Predictors of Improvement in Quality of Life Associated with
Lurasidone Treatment of Bipolar I Depression: Results from a
6-month Continuation Study
Terence Ketter, Stanford University School of Medicine
Cynthia Siu, Mariam Hassan, Krithika Rajagopalan, Andrei Pikalov,
Antony Loebel
18
Baseline Patient Characteristics of Bipolar II Compared to Bipolar
I Disorder in Trials of Acute Bipolar Depression
Jamie Mullen, AstraZeneca
Catherine Datto, Louisa Feeley, Scott LaPorte
19
Neural Correlates of Social Stress in Youth with Bipolar Disorder
Donna Roybal, University of Texas Health Sciences Center at San
Antonio
Amy Garrett, Victoria E. Cosgrove, Spencer Boucher, Jennifer
Pearlstein, Paige Staudenmaier, Jade Garneau-Fournier, Amy
Parkinson, Kiki Chang
20
The Young Mania Rating Scale in Bipolar Disorder: Evaluation of
Sleep and Rater Training
Jan Sedway, inVentiv Health Clinical
Cristina Maneru, Sandor Palfi
21
Factors Influencing the Diagnosis and Treatment of Bipolar
Depression: A Healthcare Professional Perspective
Purvi K. Smith, Health and Wellness Partners
Andrei Pikalov, Gary S. Sachs, Jani Hegarty
22
Sequence Analysis of Drug Target Genes with Suicide Severity in
Bipolar Disorder
Clement Zai, Centre for Addiction and Mental Health, University of
Toronto
Vanessa Goncalves, Vincenzo De Luca, Arun K. Tiwari, John B.
Vincent, James Kennedy
23
Immunological Stress Responsivity as a Potential Risk Factor in
Pediatric Mood Disorders
Victoria E. Cosgrove, Stanford University School of Medicine
Staudenmaier Paige, Jennifer Pearlstein, Sherrie Li, Kiki Chang
= New Investigator
83
Posters
24
Inter-rater Reliability of the Scales for Outcomes of Parkinson’s
Disease – Cognition (SCOPA-COG) in MODERATO: A Randomized,
Placebo-controlled Trial to Assess the Effect of Rasagiline on Mild
Cognitive Impairment in PD Patients
Kari Nations, INC Research
Robin C. Hilsabeck, Russell Tanenbaum, ElizaBeth Grubb, Azhar
Choudhry
25
Risk-based Monitoring for Aberrant Rating Patterns and Patient
Selection Anomalies in Global Schizophrenia Trials
David Daniel, Bracket Global, LLC
Alan Kott
26
Feasibility, Integrity and Efficiency of the Sequential Parallel
Comparison Clinical Trial Design
Marc de Somer, Alkermes, Inc.
Yangchun Du, Asli Memisoglu, Randall D. Marshall, Richard LeighPemberton, Bernard L. Silverman, Elliot Ehrich, Maurizio Fava
27
Blinded Dual Ratings Confirm Primary Site-based Ratings in an
MDD Trial
Richard Leigh-Pemberton, Alkermes, Inc.
Asli Memisoglu, Steven D. Targum, J Cara Pendergrass, Philip Rauh,
Randall D. Marshall, Bernard L. Silverman, Marc de Somer, Elliot
Ehrich
28
Complexity in Protocol Design: Does It Lead to Better Clinical
Trial Outcomes?
Robert Molpus, CNS Healthcare
Patricia Brown, Rebecca Hummel, Mark Joyce, Linda Harper, Terri
Wood, Angela Menosky, John D. Ehrhardt, Ruth Hummel
29
Impact of BPRS Interview Length on Ratings Precision during a
Schizophrenia Trial
Steven D. Targum, Clintara, LLC
J. Cara Pendergrass, Laura Zumpano, Philip Rauh, Nicholas
DeMartinis
30
Attenuation of Impulsivity in Bipolar Alcoholics Who Reduce
Heavy Drinking: Prospective Evidence from a Randomized
Placebo-controlled Trial
Bryan Tolliver, Medical University of South Carolina
James J. Prisciandaro, Delisa Brown, Helena Brenner
84
Posters
31
Efficacy of Quetiapine-XR Monotherapy or Adjunctive Therapy
to Antidepressant in Acute Major Depressive Disorder with
Generalized Anxiety Disorder: A Randomize, Placebo-controlled
Pilot Study
Keming Gao, Case Western Reserve University
32
Does Algorithm-based Depression Care Mitigate Cognitive
Decline in Older Adult Outpatients?
Aaron M. Koenig, Western Psychiatric Institute & Clinic
Meryl A. Butters, Charles F. Reynolds
33
Pro-cognitive Effects of Ketamine and Underlying
Neurocircuitry in Subjects with MDD as Assessed by fMRI and
Neuropsychological Testing
Lynnette A. Averill, Yale School of Medicine, National Center for PTSD
34
Confirming MDDScore as an Aid in the Diagnosis of Major
Depressive Disorder
John A. Bilello, Ridge Diagnostics, Inc.
Linda M. Thurmond, Katie Smith, Robert A. Rubin, Suzin M.
Wright, Floyd Taub, Michael E. Henry, Richard C. Shelton, George I.
Papakostas
35
The Effect of Vortioxetine on Sexual Dysfunction during the
Treatment of Adults with Major Depressive Disorder (MDD) or
Generalized Anxiety Disorder (GAD)
Anita H. Clayton, University of Virginia
Paula L. Jacobsen, Atul R. Mahableshwarkar, William Palo, Yinzhong
Chen, Marianne Dragheim
36
The Effects of Buprenorphine and Samidorphan, Alone and
in Combination, on Monoamine Release within the Nucleus
Accumbens Shell and Medial Prefrontal Cortex of Male Wistar
Rats
Daniel Deaver, Alkermes, Inc.
Jacobi I. Cunningham, Mark S. Todtenkopf, Reginald L. Dean, David
Eyerman
37
The Neurocircuitry of Increased Inflammation in Depression:
Preliminary Findings
Jennifer C. Felger, Emory University School of Medicine
Zhihao Li, Ebrahim Haroon, Bobbi Woolwine, Andrew H. Miller
= New Investigator
85
Posters
38
Anhedonia and Irritability as Correlates of Adverse Clinical
Features in Adolescent Major Depression
Vilma Gabbay, Icahn School of Medicine at Mount Sinai, Nathan S.
Kline Institute for Psychiatric Research
Amy R. Johnson, Ana I. Vallejo, Amira Hanna
39
A Dual-probe Microdialysis Investigation of the Interaction
Between Lisdexamfetamine Dimesylate (LDX) and S-citalopram
on CNS Monoamines – Evidence for Synergistic Augmentation of
Serotonin and Dopamine Efflux
Peter Hutson, Shire
David Heal, Helen L. Rowley, Rajiv S. Kulkarni
40
Determination of the Monoaminergic Interactions between
Lisdexamfetamine Dimesylate (LDX) and Duloxetine Reveals a
Synergistic Augmentation of Dopamine Efflux in the Nucleus
Accumbens and Striatum
Peter Hutson, Shire
Helen L. Rowley, Rajiv Kulkarni, David J. Heal
41
Safety and Tolerability of Vortioxetine 15 and 20 mg in Subjects
with Major Depressive Disorder (MDD): A Phase 3, Long-term,
Open-label Extension Study
Paula L. Jacobsen, Takeda Development Center Americas, Inc.
Linda Harper, Michael Serenko, Serena Chan, Atul R.
Mahableshwarkar
42
Efficacy and Safety of Vilazodone 20 Mg and 40 Mg in Major
Depressive Disorder: A Randomized, Double-blind, Placebo- and
Active-controlled Trial
Arif Khan, Northwest Clinical Research Center
Carl Gommoll, Maju Mathews, Dalei Chen, Rene Nunez
43
Optimizing the Response to TMS in Major Depression through
Intensive Concomitant Medication Management
Kimberly M. Lavigne, Louisiana State University
James G. Barbee, Tonya C. Hansel, Joshua F. Jansen, Jose CalderonAbbo
44
Edivoxetine as Adjunctive Treatment for Patients with Major
Depressive Disorder Who Are Partial Responders to Selective
Serotonin Reuptake Inhibitor Treatment: 3 Randomized, Placebocontrolled, Double-blind Studies
James M. Martinez, Eli Lilly and Company
Susan G. Ball, Lauren B. Marangell, Margaret B. Ferguson, Beth A.
Pangallo, Mary Anne Dellva, Celine Goldberger
86
Posters
45
Effects of Vilazodone on Sexual Dysfunction in Major Depressive
Disorder: A Randomized, Double-blind Trial with Placebo and
Active Controls
Maju Mathews, Forest Research Institute
Carl Gommoll, Dalei Chen, Rene Nunez
46
Do the Dissociative Side Effects of Ketamine Mediate Its
Antidepressant Effects?
Mark J. Niciu, National Institutes of Health, National Institute of Mental
Health
David Luckenbaugh, Dawn F. Ionescu, Neal Nolan, Erica M. Richards,
Nancy Brutsche, Sara Guevara, Carlos Zarate
47
In MDD Patients Switched After an Inadequate Response, the
Efficacy and Tolerability of Vortioxetine versus Agomelatine is
Independent of Previous Antidepressant Treatment
George I. Papakostas, Massachusetts General Hospital, Harvard
Medical School
Rebecca Z. Nielsen, Marianne Dragheim
48
Adjunctive Lanicemine (AZD6765) in Patients with Major
Depressive Disorder and a History of Inadequate Response to
Antidepressants: Primary Results from a Randomized, Placebocontrolled Study (PURSUIT)
Gerard Sanacora, Yale University School of Medicine
Michael Johnson, Arif Khan, Sarah D. Atkinson, Robert Riesenberg,
Juan Schronen, Michael A. Burke, John Zajecka, Hong-Lin Su, Sanjay
Mathew, Sanjeev Pathak
49
Impact of a Culturally-focused Psychiatric Consultation on
Depressive Symptoms among Spanish- and English-speaking
Latinos in Primary Care
Nhi-Ha Trinh, Depression Clinical and Research Program,
Massachusetts General Hospital
Ilana Huz, Lara Traeger, Trina Chang, Maurizio Fava, Albert Yeung,
Stephen Gilman
50
Association between Physicians’ Expectations and Clinical
Response: Re-analysis of Data from the Hypericum Depression
Trial Study Group
Sagar A. Vijapura, Harvard Medical School
Justin Chen, George I. Papakostas, Lee Baer, Alisabet Clain, Maurizio
Fava, David Mischoulon
= New Investigator
87
Posters
51
A Case Mix Severity Index for Depression
Mark Zimmerman, Rhode Island Hospital
52
How Many Different Ways Do Patients Meet the Diagnostic
Criteria for Major Depressive Disorder?
Mark Zimmerman, Rhode Island Hospital
53
Randomized Controlled Safety and Efficacy Trials of
Lisdexamfetamine Dimesylate for Adults with Moderate to Severe
Binge Eating Disorder
Susan McElroy, University of Cincinnati College of Medicine
James Hudson, M. Celeste Ferreira-Cornwell, Jana Radewonuk, Maria
Gasior
54
Prazosin for Nightmares in Patients with Eating Disorders: A Case
Series
Padmapriya Musunuri, Einstein Medical Center
Gibson T. George, Richard Jaffe
55
Effects of Scopolamine on Working Memory Task and Resting
Functional Connectivity Using fMRI in Healthy Korean Subjects
Brett A. English, PAREXEL International
Niki Osimo, Alex Korb, Adam Bazih, Lev Gertsik, Larry Ereshefsky
56
Improving Psychopharmacology Education and Practice: The
Quandary of Getting Data and Information to the Teachers
Ira Glick, Stanford University School of Medicine
Richard Balon, Sidney Zisook
57
Is Pain a Risk Factor for Suicidality as Assessed by the C-SSRS
and S-STS? Findings from an Adult Inpatient Psychiatric Sample
Ahmad Hameed, Penn State College of Medicine
Amanda M. White, Michael Mitchell, Eric A. Youngstrom, Roger E.
Meyer, Alan J. Gelenberg
58
A Prospective Open-label Trial of Memantine Hydrochloride for
the Treatment of Core Features of Autism Spectrum Disorder in
High-functioning Adults
Gagan Joshi, Massachusetts General Hospital/Harvard Medical
School
Janet Wozniak, Ronna Fried, Laura Tarko, Stephannie L. Furtak, Leah
Feinberg, Joseph Biederman
88
Posters
59
The Effect of Citicoline Supplementation on Motor Speed and
Attention in Adolescent Males
Erin McGlade, University of Utah Brain Institute, University of Utah
Department of Psychiatry
Allison Locatelli, Jennifer DiMuzio, Miho Kizaki, Eri Nakazaki,
Toshikazu Kamiya, Deborah Yurgelun-Todd
60
Evaluation of the Implementation of Psychotropic Medication
Utilization Parameters for Children and Adolescents in Texas
Foster Care
M. Lynn Crismon, The University of Texas at Austin
James A. Rogers, Alan Shafer, Nina J. Muse
61
How to Collaborate with CRA, from a China Clinical Site
Perspective
Yifeng Shen, Shanghai Mental Health Center
Huafang Li
62
Tolerability and Safety Profile of Aripiprazole Once-monthly in the
Treatment of Schizophrenia: A Pooled Analysis from the Safety
Database of 11 Completed or Ongoing Trials
Ross A. Baker, Otsuka Pharmaceutical Development &
Commercialization, Inc.
Peter Hertel, Anna-Greta Nylander, Na Jin, Anna Eramo, Ruth Duffy,
Robert D. McQuade, Timothy Peters-Strickland
63
Leucocytes Point of Care Measurement in Clozapine Therapy
Dan Cohen, Mental Health Organization North-Holland
Jan Bogers
64
Early Improvement Predicts Endpoint Response to Lurasidone in
Schizophrenia: Pooled Analysis of Five Double-blind Trials
Christoph Correll, Hofstra North Shore-LIJ School of Medicine in New
York
Andrei Pikalov, Jay Hsu, Josephine Cucchiaro, Robert Goldman,
Antony Loebel
65
Safety and Tolerability of Cariprazine in Long-term Treatment of
Schizophrenia: Integrated Summary of Safety Data
Andrew J. Cutler, Florida Clinical Research Center, LLC
Henry A. Nasrallah, Yao Wang, Kaifeng Lu, Krisztián Nagy, István
Laszlovszky, Suresh Durgam
89
Posters
66
The Effect of Previous Dose of Oral Aripiprazole (10 or 30 Mg/
Day) on the Efficacy and Tolerability of Aripiprazole Oncemonthly: Post-hoc Analyses of Two Double-blind, Randomized,
Controlled Trials
Anna Eramo, H. Lundbeck A/S
Ross A. Baker, Anna-Greta Nylander, Lan-Feng Tsai, Timothy PetersStrickland, Raymond Sanchez
67
Paliperidone Palmitate Delays Relapse and Maintains Functioning
in Patients with Stabilized Psychotic and Mood Symptoms of
Schizoaffective Disorder
Dong-Jing Fu, Janssen Scientific Affairs, LLC
Larry Alphs, Jean-Pierre Lindenmayer, Nina R Schooler, Richard B.
Simonson, Ibrahim Turkoz, David P. Walling
68
Eszopiclone for Insomnia Treatment in Clinically Stable Patients
with Schizophrenia: A Double-blind, Randomized, Placebocontrolled Trial
Sinan Guloksuz, Yale University School of Medicine
Cenk Tek, Laura Palmese, Andrew Krystal, Pamela DeGeorge, Erin
Reutenauer
69
Virtual Reality Functional Capacity Assessment: Progress on the
Validation of a Computerized Assessment of Functional Skills
Richard S.E. Keefe, NeuroCog Trials, Duke University
Stacy Ruse, Vicki G. Davis, Alexandra S. Atkins, Thomas L. Patterson,
Meera Narasimhan, Philip Harvey
70
Effect of Long-term Treatment with Lurasidone or Risperidone on
Metabolic Syndrome Status in Patients with Schizophrenia
John Newcomer, Florida Atlantic University
Andrei Pikalov, Kei Watabe, Josephine Cucchiaro, Krithika
Rajagopalan, Antony Loebel
71
Aripiprazole Once-monthly for Long-term Maintenance Treatment
of Schizophrenia: A 52-week Open-label Study
Timothy Peters-Strickland, Otsuka Pharmaceutical Development &
Commercialization, Inc.
Ross A. Baker, Robert D. McQuade, Anna Eramo, Pamela P. Perry,
Brian R. Johnson, Raymond Sanchez, Anna R. Duca
90
Posters
72
Psychometric Properties of the Dynamic Social Cognition Battery
(DSCB), a Comprehensive Toolkit for Social Cognition in Patients
with Schizophrenia
Brian Rothman, ProPhase LLC
Anzalee Khan, Luka Lucic, Linda Gao, Mark Opler
73
Prevalence, Healthcare Utilization, and Cost of Patients Dual
Diagnosed with Schizophrenia and an Alcohol Use Disorder
Bernard L. Silverman, Alkermes, Inc.
Jacqueline Zummo, Lauren E. DiPetrillo, Cathy Garabedian
74
Insight into Illness and Uncooperativeness in Chronic
Schizophrenia
Cynthia Siu, Data Power
Ofer Agid, Mary Waye, Gary Remington, Philip Harvey
75
Safety and Efficacy of Aripiprazole Lauroxil: Results from a Phase
3, Multicenter, Randomized, Double-blind, Placebo-controlled
Study in Subjects with Acute Exacerbation of Schizophrenia
Srdjan R. Stankovic, Alkermes, Inc.
Robert Risinger, Yangchun Du, Jacqueline Zummo, Lisa Corey,
Bernard L. Silverman, Elliot Ehrich
76
How Does the NSA-4 Compare to the NSA-16?
Janet Williams, MedAvante, Inc.
Lori M. Garzio, Doug Osman, Danielle Popp
77
Inhaled Loxapine and Intramuscular Lorazepam in Healthy
Volunteers: A Randomized, Placebo-controlled Drug-drug
Interaction Study
Paul P. Yeung, Teva Pharmaceuticals
Daniel A. Spyker, James V. Cassella, Randall R. Stoltz
78
Validity Characteristics of the Cognitive Assessment Interview
(CAI) in Stable Outpatients with Schizophrenia
Robert Goldman, Sunovion Pharmaceuticals, Inc.
Joseph Ventura, Cynthia Siu, Antony Loebel
79
The National Pregnancy Registry for Atypical Antipsychotics:
Effects of Fetal Exposure on Risk for Major Malformations and
Extrapyramidal Symptoms
Lee S. Cohen, Massachusetts General Hospital
Adele C. Viguera, Kathryn McInerney, Molly Kwiatkowski, Shannon
Murphy, Elizabeth Lemon, Sonia Hernandez-Diaz
91
Posters
80
Raving and Depression in Opiate Dependent Mentally Ill Receiving
Suboxone and Group CBT Therapy
Tanya Alim, Howard University
Leslie Adams, Didier Grandjean, Steven Tulin, Elizabeth CarpenterSong, Moria Hipolito, Loretta D. Peterson, William B. Lawson
81
Efficacy and Safety of ABT-126 as a7 Nicotinic Cholinergic
Agonist, in Treatment of Cognitive Impairment Associated with
Schizophrenia: Results from a Proof Concept Study
George Haig, AbbVie, Inc.
Jeff Baker, Weining Robieson, Earle Bain, Ahmed A. Othman
92
Author Index
74
81
26, 73, 81
92
70
70
91
92
51
79, 80, 90
34
26, 49
72
32
70
73, 90
87
69
12, 57
85
74
78
87
92
92
78, 79, 89, 90
48
86
88
86
81
71, 74, 75
88
69
70
69
39
71
59
26, 70
70, 82, 88
85
78
70
75
74
89
8, 14, 43, 68
Boucher, Spencer
Bowen, Richard
Bradshaw, Mark
Brennan, Francis X.
Brenner, Helena
Briggs, Josephine
Brimijoin, Stephen
Broich, Karl
Brown, Delisa
Brown, Patricia
Brown, Walter
Brutsche, Nancy
Bryan, Joseph and Kathleen
Bryson, Heather
Budziszewska, Bogusława
Bui, Khanh
Bundren, J. Clark
Bunker, Mark
Burch, Daniel
Burdick, Katherine
Burghardt, Kyle
Burke, Michael A.
Busner, Joan
Butters, Meryl A.
Bymaster, Frank
Calabrese, Joseph R.
Calarge, Chadi
Calderon-Abbo, Jose
Camprodon, Joan
Camsari, Ulas M.
Cantillon, Marc
Caroff, Stanley N.
Carpenter-Song, Elizabeth
Carroll, Kathleen
Cassella, James V.
Chan, Serena
Chang, Kiki
Chang, Trina
Cheetham, S.
Chen, Changzheng
Chen, Dalei
Chen, Justin
Chen, Laishun
Chen, Yinzhong
Chengappa, Roy K.N.
Chen, Yinzhang
Cheshire-Kinney, Kim
Childress, Ann
93
83
35, 69
69
82
84
13, 57
31
16
84
84
36, 73
87
65
73
71, 74, 75
76
80
25, 74
73
33, 49
26, 70
87
81
85
69
33, 71
50
86
26, 48
81
65
29
92
81
80, 91
86
83
87
77
74
75, 86, 87
87
74
85
49
75
78
69
Author Index
Aaronson, Scott T.
Abulseoud, Osama
Achtyes, Eric
Adams, Leslie
Addolorato, Giovanni
Adler, Lenard
Agid, Ofer
Alim, Tanya
Alpert, Jonathan
Alphs, Larry
Altemus, Margaret
Andreazza, Ana
Ansari, Arash
Anton, Raymond F.
Aoun, Elie G.
Atkins, Alexandra S.
Atkinson, Sarah D.
Atwood, Craig
Austin, Christopher
Averill, Lynnette A.
Bachman, David
Badner, Judith A.
Baer, Lee
Bain, Earle
Baker, Jeff
Baker, Ross A.
Baldwin, David
Ball, Susan G.
Balon, Richard
Barbee, James G.
Baskind, Robert
Basta-Kaim, Agnieszka
Bazih, Adam
Beaver, Jessica
Bédard, Anne-Claude V.
Bencherif, Merouane
Ben-Zee, Dror
Berk, Michael
Bertolino, Alessandro
Bhuvaneswaran, Chaya
Biederman, Joseph
Bilello, John A.
Bishop, Jeffrey R.
Blair, James
Bodkin, J. Alexander
Bogan, Richard K.
Bogers, Jan
Borges, Silvana
Author Index
Choudhry, Azhar
Christine, Mazzucco
Chrones, Lambros
Citrome, Leslie
Clain, Alisabet
Clark, Crystal
Clarke, Diana E.
Clayton, Anita
Clayton, Anita H.
Coffey, Barbara
Cohen, Dan
Cohen, Lee S.
Compton, Michael T.
Corey, Lisa
Correll, Christoph
Cortese, Bernadette M.
Cosgrove, Victoria E.
Courbay, Zane
Craighead, W. Edward
Crismon, M. Lynn
Cross, Alan
Cucchiaro, Josephine
Cunningham, Jacobi I.
Curzytek, Katarzyna
Cutler, Andrew J.
Daly, Ella
Daniel, David
Datto, Catherine
Davidson, Richard J.
Davis, Alan T.
Davis, Heather L.
Davis, Lori
Davis, Michael
Davis, Vicki G.
Deal, Linda
Dean, Reginald L.
Deaver, Daniel
Debelle, Marc
DeBoer, Peter
DeBonis, Dan
Deckersbach, Thilo
DeGeorge, Pamela
Deligiannidis, Kristina
Dellva, Mary Anne
Delong, Liz
De Luca, Vincenzo
DeMartinis, Nicholas
84
69
75
17, 20, 74
87
47, 80
33, 78
75
85
73
78, 89
34, 91
66
91
17, 19, 20, 25, 39,
66, 89
74
61, 71, 83
42
72
89
36, 69
71, 72, 78, 89, 90
85
75
69, 74, 81, 89
69
84
71, 82, 83
31
81
31
16, 19, 25, 33
26, 49
73, 90
77
85
85
78
69
81
17
90
20, 49
86
45
83
84
Dennis, Donn M.
Denton, Wayne H.
Derbyshire, Katherine L.
de Somer, Marc
Detka, Jan
Detke, Michael
Dhossche, Dirk M.
DiMuzio, Jennifer
DiPetrillo, Lauren E.
Dirks, Bryan L.
Dodd, Seetal
Dragheim, Marianne
Drevets, Wayne
Du, Yangchun
Duca, Anna R.
Duda, Weronika
Duffy, Farifteh
Duffy, Ruth
Duhoux, Stephanie
Durgam, Suresh
Dvergsten, Chris
Edwards, Emmeline
Efros, Mitchell
Ehrhardt, John D.
Ehrich, Elliot
Ellingrod, Vicki L.
English, Brett A.
Eramo, Anna
Ereshefsky, Larry
Escher, Tobie
Evins, Eden
Eyerman, David
Falk, Daniel E.
Faraone, Stephen V.
Farchione, Tiffany
Farr, Gaston
Faucett, James
Fava, Maurizio
Feeley, Louisa
Feinberg, Leah
Felger, Jennifer
Ferguson, Margaret B.
Ferreira-Cornwell, M.
Fertig, Joanne B.
Fiedorowicz, Jess G.
Fischer, E. Grace
94
77
70
77
84
71
30, 37, 76
29
89
75, 91
17
71
76, 85, 87
69
49, 84, 91
90
75
78
89
26, 70
72, 78, 89
69
30, 45
73
84
84, 91
70
88
78, 79, 89, 90
76, 88
74
17
85
81
70, 82
17, 19, 25, 50
69
73
16, 17, 20, 50, 58,
66, 73, 75, 76, 84,
87
83
88
26, 85
86
88
81
46
71
Author Index
Fleischhacker, W.
Flynn, Martina J.
Fochtmann, Laura
Francis, Andrew
Frank, Ellen
Freeman, Marlene
Friedman, Edward S.
Fried, Ronna
Frye, Mark A.
Fu, Dong-Jing
Furmaga, Kevin M.
Furtak, Stephannie L.
Gabbay, Vilma
Gale, Phillip D.
Gao, Keming
Gao, Linda
Garabedian, Cathy
Gardner, Kathryn
Garneau-Fournier, Jade
Garrett, Amy
Garzio, Lori M.
Gasior, Maria
Gastfriend, David
Gaynes, Bradley
Geibel, Brooke
Gelenberg, Alan
Gelovich, Mary
George, Gibson T.
George, Sanju
Gerretsen, Philip
Gertsik, Lev
Gibbons, Robert
Gift, Thomas
Gilman, Stephen
Glick, Ira
Gliddon, Emma
Goff, Donald C.
Goldberger, Celine
Goldberg, Joseph
Goldman, Robert
Golembiowska, Krystyna
Gommoll, Carl
Goncalves, Vanessa
Gosden, J.
Grabb, Meg
Grandison, Lindsey
Grandjean, Didier
Grant, Jon E.
78
73
78
29
61, 72
16, 20, 34, 48, 73
37
70, 88
76
90
81
88
73, 75, 86
81
72, 85
71, 79, 91
91
82
83
83
91
77, 88
70
17, 48
30
20, 45, 71, 77, 88
76
88
76
26, 79
88
61, 73
81
87
20, 77, 88
71
51, 66
86
20, 33, 44, 51, 82
89, 91
75
74, 75, 86, 87
83
77
52, 59
19, 25
92
77
Greenberg, William M.
Greist, John
Grigoriadias, Sophie
Grosser, Bernard
Grubb, ElizaBeth
Guevara, Sara
Guloksuz, Sinan
Haass-Koffler, Carolina
Haig, George
Halstead, Scott
Hameed, Ahmad
Hanina, Adam
Hanna, Amira
Hanover, Rita
Hansel, Tonya C.
Haroon, Ebrahim
Harper, Linda
Harris, Herbert
Harris, Margret S. H.
Harrison, John E.
Harvey, Philip
Hassan, Mariam
Hassman, Howard
Heal, David
Heemskerk, Jill
Hegarty, Jani
Heidi, De Smedt
Henry, Michael E.
Herman, Barry
Hernandez, David
Hernandez, Mariely
Hernandez-Diaz, Sonia
Hert, Marc De
Hertel, Peter
Hildebrandt, Tom
Hill, Lauren
Hillefors, Mi
Hilsabeck, Robin C.
Hipolito, Moria
Hosford, David
Hough, David
Hsu, Jay
Hsu, Timothy
Hsu, Wei-Chun
Hu, Chunling
Hudson, James
Hummel, Rebecca
Hummel, Ruth
95
74
18
6
69
84
87
90
70
92
73
77, 88
39
86
69, 81
86
85
84, 86
82
78
75
90, 91
83
76
77, 86
52
83
69
85
77
78
82
34, 91
79
89
70
15, 19, 25
66
84
92
36, 69
79
89
69, 81
82
76
88
84
84
Author Index
Huntley, Kristen
Hurt, Stephen W.
Hutson, Peter
Huz, Ilana
Insel, Thomas
Ionescu, Dawn F.
Iosifescu, Dan V.
Iovieno, Nadia
Jacobsen, Paula L.
Jaffe, Richard
Jansen, Joshua F.
Jett, John
Jha, Amishi
Jin, Na
Johnson, Amy R.
Johnson, Ann E.
Johnson, Brian R.
Johnson, Joe
Johnson, Michael
Jones, Warren
Joseph, Melissa
Joshi, Gagan
Joyce, Mark
Kamiya, Toshikazu
Kane, John
Kapczinski, Flavio
Kasula, Varun
Keefe, Richard
Kemp, David
Kenna, George
Kennedy, James
Kennedy, Patrick
Kent, Justine
Keshavan, Matcheri S.
Ketter, Terence
Kezic, Iva
Khan, Anzalee
Khan, Arif
Khin, Ni
Kim, Sanghyeon
Kim, Seonghwan
Kim, Sungman
King, Bryan H.
Kinon, Bruce
Kishimoto, Taishiro
30
69
77, 86
87
9, 11, 56, 57
87
51, 60
72
75, 85, 86
88
86
69
30
89
75, 86
81
90
81
87
59
69
88
84
89
20, 39, 46, 66, 67,
78
46
76
18, 73, 90
38, 46
70
83
10, 56
35, 69
78
18, 33, 37, 59, 72,
82, 83
69
71, 79, 91
20, 36, 37, 73, 86,
87
7, 14, 43, 68
79
76
76
59
16, 19
46
Kizaki, Miho
Kocsis, James H.
Koenig, Aaron
Korb, Alex
Kott, Alan
Kraemer, Helena
Kremer, Charlotte
Kroger, Hans
Krone, Beth
Kronstein, Phillip
Krupitsky, Evgeny
Krystal, Andrew
Kubera, Marta
Kulkarni, Rajiv
Kupfer, David
Kurek, Anna
Kwiatkowski, Molly
Laezza, Fernanda
Lally, Níall
Landsberg, Wally
Lane, Rosanne
LaPorte, Scott
Lason, Wladyslaw
Laszlovszky, István
Lauder, Sue
Laughren, Thomas
Lavigne, Kimberly M.
Lawson, William B.
Leggio, Lorenzo
Leigh-Pemberton, Richard
Lemon, Elizabeth
Leppink, Eric
Leśkiewicz, Monika
Leslie, Kimberly R.
Levenson, Jessica C.
Li, Huafang
Li, Sherrie
Li, Zhihao
Liebowitz, Michael
Lim, Kelvin O.
Lindenmayer, Jean-Pierre
Ling, Walter
Lippiello, Patrick
Litman, Robert E.
Litten, Raye
Litten, Raye Z.
Locatelli, Allison
96
89
16
26, 85
88
84
18
18
71, 72
70
14, 68
70
90
71, 74, 75
86
16, 18, 52, 57, 72
71
91
82
75
79
69
71, 82, 83
75
72, 78, 89
71
16, 18, 51, 67
86
92
70
75, 84
91
77
71, 74, 75
74
72
79, 89
83
85
35, 47, 60, 69, 81
30
79, 90
70
69
72
16, 31
32, 38, 81
89
Author Index
Loebel, Antony
Loewy, Rachel
Loft, Henrik
Lombard, Jay
Lophaven, Søren N.
Loskie, Eileen
Lucic, Luka
Luckenbaugh, David
Lu, Kaifeng
Mackin, Scott
Maes, Michael
Mahableshwarkar, Atul R.
Mahalchick, Lucy
Ma, Kaizong
Malhotra, Anil
Maneru, Cristina
Manji, Husseini
Mao, Lian
Mao, Yongcai
Marangell, Lauren B.
Marc, Ceusters
Marchant, Barrie K.
Marder, Steve
Marshall, Kay
Marshall, Randall D.
Martinez, James M.
Masand, Prakash
Mathew, Sanjay
Mathews, Maju
Mattes, Jeffrey
Matthews, Mark
Mattingly, Gregory
Matyas, Gary R.
Mavissakalian, Matig
McCracken, James T.
McElroy, Susan
McEvoy, Joseph P.
McGlade, Erin
McInerney, Kathryn
McKinney, Anthony
McQuade, Robert D.
Memisoglu, Asli
Menosky, Angela
Merritt-Davis, Orlena
Meyer, Roger E.
Michelson, David
Miller, Andrew H.
71, 72, 78, 79, 82,
83, 89, 90, 91
67
76
82
75
77
71, 91
75, 87
72, 78, 89
50
75
75, 76, 85, 86
78
71
16, 18
83
8, 15, 16, 55, 56
80
78
86
69
81
16, 18
81
60, 69, 75, 84
86
76
60, 76, 87
74, 75, 86, 87
77
61
79
31
47
59
58, 77, 88
47
89
91
69
89, 90
70, 75, 84
84
74
77, 88
16
85
Millet, Robert
Mischoulon, David
Miskowiak, Kamilla
Miskowiakm, Kamilla
Mitchell, Michael
Mohammad, Othman
Molpus, Robert
Monti, Louis
Montoya, Ivan
Mościcki, Eve K.
Mullen, Jamie
Murphy, Shannon
Murrough, James W.
Muse, Nina J.
Musunuri, Padmapriya
Nagy, Krisztián
Nakajima, Shinichiro
Nakamura, Richard
Nakazaki, Eri
Narasimhan, Meera
Narrow, William
Nasrallah, Henry A.
Nations, Kari
Neill, Joanna C.
Nelson, Craig
Nenov, Miroslav
Newcomer, John
Newcorn, Jeffrey
Nguyen, Theresa
Niciu, Mark
Nicol, Ginger E.
Nielsen, Rebecca Z.
Nierenberg, Andrew
Nimgaonkar, Vishwajit
Nolan, Neal
Norquist, Grayson
Nueten, Luc Van
Nugent, Allison C.
Nugter, Annet
Nunez, Rene
Nylander, Anna-Greta
O’Brien, Catherine
O’Connor, Joann
Odlaug, Brian L.
Olsen, Christina Kurre
O’Malley, Stephanie
Ondrus, Matej
O’Neill, James
97
76
73, 87
26
48
77, 88
72
84
69
19
34, 78
83
91
60
89
88
72, 89
26
13, 57
89
90
33, 34, 78
89
84
81
18, 50
82
20, 71, 90
70
72
26, 87
71
87
16, 37, 67
78
87
67
69
75
78
74, 75, 86, 87
89, 90
69, 81
74
77
75
16
77
78
Author Index
Opler, Mark
Oshibuchi, Hidehiro
Osimo, Niki
Oslin, David
Osman, Doug
Osser, David
Othman, Ahmed A.
Paige, Staudenmaier
Paik, Jong-Woo
Palfi, Sandor
Palmese, Laura
Palo, William
Pangallo, Beth A.
Panova-Elektronova, Neli
Papakostas, George I.
Parkinson, Amy
Pathak, Sanjeev
Patkar, Ashwin
Patterson, Thomas L.
Pearlstein, Jennifer
Pedraza, Juan D.
Pendergrass, J. Cara
Perez-Rodriguez, M.
Perry, Pamela P.
Persson, Jennie K.
Petersen, Timothy
Peterson, Loretta D.
Peters-Strickland, Timothy
Petrakis, Ismene L.
Petrides, Georgios
Phillips, Debra
Phillips, Katharine
Pikalov, Andrei
Pilar, Lim
Piser, Tim
Plovnick, Robert M.
Pooley, James
Popescu, Marlene
Popp, Danielle
Posener, Joel
Pothier, David D.
Potter, William
Prasad, Konasale M.
Price, Blair
Priest, Jacob B.
Prisciandaro, James J.
Prow, M.
71, 79, 91
26
88
38
91
72
92
83
76
83
90
85
86
82
59, 72, 85, 87
83
76, 87
76
90
83
70
84
26, 49
90
77
60
92
49, 78, 89, 90
38
29
78, 79
18, 19, 25
33, 71, 78, 79, 82,
83, 89, 90
69
76
78
73
77
91
76
79
16, 52
78
76
70
84
77
Quirk, Michael
Rabinowitz, Jonathan
Radewonuk, Jana
Rajagopalan, Krithika
Raju, Karishma
Rapaport, Mark H.
Rapoport, Stanley
Rappaport, Bob A.
Rauh, Philip
Regulska, Magdalena
Reilly, James L.
Reimherr, Frederick W.
Reimherr, Kathleen
Rele, Shilpa
Remington, Gary
Ressler, Kerry
Reutenauer, Erin
Reynolds, Charles F.
Richards, Erica M.
Riesenberg, Robert
Rishton, Melanie
Risinger, Robert
Robieson, Weining
Rodriguez, Stephen
Rogers, James A.
Romano, Steve
Rorick-Kehn, Linda
Rose, Andrew C.
Rosenbaum, Jerrold
Rosenberg, Leon I.
Rothman, Brian
Rowley, Helen L.
Roybal, Donna
Rubin, Jonathan
Rubin, Robert A.
Runion, Jennifer
Ruse, Stacy
Rush, A. John
Ruth, Adam
Ruvuna, Francis
Ryan, Megan L.
Ryan, Neil
Ryan, Patrick
Sachs, Gary S.
Sahoo, Saddichha
Sajatovic, Martha
Salman, Ester
Saltz, Bruce
98
76
30, 35
88
82, 83, 90
71
15, 17, 19, 20, 25
71
17
84
75
78
81
81
76
91
72
90
85
87
87
77
91
92
78, 80
89
17, 18
82
81
18
76
71, 79, 91
86
26, 83
35
85
74
90
5, 25
74
74
81
18
79
81, 83
50
18
81
18
Author Index
Sanacora, Gerard
Sanchez, Raymond
Sarampote, Chris
Sarma, Kaushik
Saunders, Erika
Savitz, Jonathan
Scahill, Lawrence
Schaefer, Eric
Schneider, Lon S.
Schooler, Nina R.
Schronen, Juan
Schulz, Kurt
Schweiger, Julia A.
Scott, Rachel
Sears, Peter
Sedway, Jan
Segreti, Anthony
Serenko, Michael
Shafer, Alan
Shavkunov, Alexander
Shay, Michelle
Shelton, Richard
Shen, Yifeng
Shiromani, Priyattam
Shurtleff, David
Silk, Jennifer
Silva, Robert
Silverman, Bernard L.
Simeonova, Diana
Simon, Greg
Simonson, Richard B.
Simpson, Tracy
Singareddy, Ravi
Singh, Jaskaran
Siu, Cynthia
Skolnick, Phil
Slusarczyk, Joanna
Smart, LeAnn D.
Smit, Andries
Smith, Katie
Smith, Purvi K.
Smith, Robert C.
Sofuoglu, Mehmet
Sorensen, Per
Spencer, Thomas
Spyker, Daniel A.
Stang, Paul
60, 66, 76, 87
78, 90
52
71, 72
71
46
59
71
65
17, 19, 25, 39, 46,
47, 67, 90
87
70
71
82
74
83
69
86
89
82
71, 82
18, 51, 76, 85
79, 89
74
30
61
71, 72
70, 84, 91
26, 72
45, 67
90
38
74
35, 60, 69
82, 83, 91
11, 17, 31, 57
74, 75
73, 81
78
85
83
80
81
32
70
80, 91
79
Stankovic, Srdjan R.
Starr, H. Lynn
Staudenmaier, Paige
Steans, Tammy A.
Stein, Mark
Stevenson, James M.
Stoltz, Randall R.
Stout, Robert L.
Strachan, Martha
Stroescu, Ioan
Su, Hong-Lin
Suppes, Trisha
Surman, Craig
Sutor, Shari
Swartz, Holly
Sweeney, John A.
Swift, Robert
Tandon, Rajiv
Tanenbaum, Russell
Tang, Xiongwen
Targum, Steven D.
Tarko, Laura
Taub, Floyd
Tauscher-Wisniewski, Sitra
Tek, Cenk
Thase, Michael
Thurmond, Linda M.
Tiwari, Arun K.
Tocco, Michael
Todtenkopf, Mark S.
Tohen, Mauricio
Toler, Steven
Tolliver, Bryan
Tomlinson, Anneka
Traeger, Lara
Trinh, Nhi-Ha
Trivedi, Madhukar
Tsai, Lan-Feng
Tulin, Steven
Turkoz, Ibrahim
Turncliff, Ryan
Tye, Susannah J.
Uhde, Thomas W.
Valjakka, Risto
Vallejo, Ana I.
Vanover, Kimberly E.
Varghese, Sajoy P.
99
91
80
83
81
70
78
91
32
74
73
76, 87
71
70
76
15, 19, 25, 61, 72
78
70
78
84
74
36, 50, 84
70, 82, 88
85
66
90
15, 17, 20, 44, 51,
75, 76
85
83
79
85
37
69
84
48, 81
87
26, 87
46, 75, 76
78, 79, 90
92
90
75
76
74
77
75, 86
36
74
Author Index
Ventura, Joseph
Viguera, Adele C.
Vijapura, Sagar A.
Vincent, John B.
Vitiello, Ben
Volk, Stephen
Vornov, James
Voss, Erica
Wagner, Ann
Wagner, Karen
Walker, Adam
Walker, Rosemary
Walling, David P.
Wang, Chao
Wang, Dana
Wang, Yao
Warnock, Julia “Jill” K.
Warren, Kenneth
Watabe, Kei
Waye, Mary
Weber, Wendy
Weiden, Peter J.
Weingard, Kerri
Welsh-Bohmer, Kathleen
Wender, Paul H.
Wesnes, Keith
White, Amanda M.
White, Stuart F.
Wilens, Timothy
Williams, Janet
Winchell, Celia
Wirth, Robert
Witkiewitz, Katie
Woods, Sarah B.
Wood, Terri
Woolwine, Bobbi
Wozniak, Janet
Wright, Jason
Wright, Suzin M.
Wu, Allen
Xu, Jane
Yaroslavsky, Yury
Yeung, Albert
Yeung, Paul P.
Yingling, Michael D.
Yonkers, Kimberly
Youngstrom, Eric A.
Yurgelun-Todd, Deborah
Zai, Clement
Zai, Gwyneth
Zajecka, John
Zarate, Carlos
91
91
87
83
17, 19, 67
78
76
79
59
19, 20
76
72
90
76
72
89
80
12, 57
82, 90
91
45
45
73
65
81
65, 76
77, 88
70
35, 69, 81
Zimmerman, Mark
Zisook, Sidney
Zukin, Stephen
Zummo, Jacqueline
Zumpano, Laura
100
19, 30, 77, 91
7, 14, 43, 68
77
32
70
84
85
82, 88
71, 82
85
78
79
74
87
80, 91
71
19, 81
77, 88
89
26, 83
26, 48
87
15, 17, 19, 35, 66,
75, 87
73, 88
20, 88
74, 78
70, 91
84
Save the Date:
2015 ASCP Annual Meeting
June 22-25, 2015
Miami Beach, Florida
www.ascpp.org
ASCP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027
phone: 615-649-3085
fax: 888-417-3311
email: info@ascpp.org